Olle Ringdén

Publications
CV
Public outreach and news

Articles

Article: CYTOTHERAPY. 2023;25(1):68-75
Immunomodulation by placenta-derived decidua stromal cells. Role of histocompatibility, accessory cells and freeze-thawing
Sadeghi B; Witkamp M; Schefberger D; Arbman A; Ringden O
Article: TRANSPLANTATION AND CELLULAR THERAPY. 2022;28(10):681-693
Characteristics of Graft-Versus-Host Disease (GvHD) After Post-Transplantation Cyclophosphamide Versus Conventional GvHD Prophylaxis
Salibaaw RM; Alousia AM; Pidala J; Arora M; Spellman SR; Hemmer MT; Wang T; Abboudg C; Ahmed S; Antin JH; Beitinjanehi A; Buchbinder DK; Byrne M; Cahn J-Y; Choen H; Hanna R; HemattiP P; Kamble RT; Kitkor CL; Laughlin M; Lekakis L; MacMillan ML; Martino R; Mehta PA; Nishihori T; Patel SS; Perales M-A; Rangarajan HG; Ringden O; Rosenthal J; Savani BN; Schultz KR; Seo S; Teshimaag T; van der Poela M; Verdonck LF; Weisdorf D; Wirk B; Yared JA; Schriber J; Champlin RE; Ciurea SO
Article: BLOOD ADVANCES. 2022;6(1):339-357
Haploidentical vs sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia
Wieduwilt MJ; Metheny L; Zhang M-J; Wang H-L; Estrada-Merly N; Marks DI; Al-Homsi AS; Muffly L; Chao N; Rizzieri D; Gale RP; Gadalla SM; Cairo M; Mussetti A; Gore S; Bhatt VR; Patel SS; Michelis FV; Inamoto Y; Badawy SM; Copelan E; Palmisiano N; Kharfan-Dabaja MA; Lazarus HM; Ganguly S; Bredeson C; Diaz Perez MA; Cassaday R; Savani BN; Ballen K; Martino R; Wirk B; Bacher U; Aljurf M; Bashey A; Murthy HS; Yared JA; Aldoss I; Farhadfar N; Liu H; Abdel-Azim H; Waller EK; Solh M; Seftel MD; van der Poel M; Grunwald MR; Liesveld JL; Kamble RT; McGuirk J; Munker R; Cahn J-Y; Lee JW; Freytes CO; Krem MM; Winestone LE; Gergis U; Nathan S; Olsson RF; Verdonck LF; Sharma A; Ringden O; Friend BD; Cerny J; Choe H; Chhabra S; Nishihori T; Seo S; George B; Baxter-Lowe LA; Hildebrandt GC; de Lima M; Litzow M; Kebriaei P; Hourigan CS; Abid MB; Weisdorf DJ; Saber W
Article: FRONTIERS IN IMMUNOLOGY. 2022;13:963445
Mesenchymal stromal cells as treatment for acute respiratory distress syndrome. Case Reports following hematopoietic cell transplantation and a review
Sadeghi B; Ringden O; Gustafsson B; Castegren M
Article: TRANSPLANTATION AND CELLULAR THERAPY. 2021;27(12):993.e1-993.e8
Planned Granulocyte Colony-Stimulating Factor Adversely Impacts Survival after Allogeneic Hematopoietic Cell Transplantation Performed with Thymoglobulin for Myeloid Malignancy
Orfali N; Zhang M-J; Allbee-Johnson M; Boelens JJ; Artz AS; Brunstein CG; McNiece IK; Milano F; Abid MB; Chee L; Diaz MA; Grunwald MR; Hematti P; Hsu J; Lazarus HM; Munshi PN; Prestidge T; Ringden O; Rizzieri D; Riches ML; Seo S; Solh M; Solomon S; Szwajcer D; Yared J; van Besien K; Eapen M
Article: JOURNAL OF CELLULAR AND MOLECULAR MEDICINE. 2021;25(22):10554-10564
Conquering the cytokine storm in COVID-19-induced ARDS using placenta-derived decidua stromal cells
Sadeghi B; Roshandel E; Pirsalehi A; Kazemi S; Sankanian G; Majidi M; Salimi M; Aghdami N; Sadrosadat H; Kochaksaraei SS; Alaeddini F; Ringden O; Hajifathali A
Article: TRANSPLANTATION AND CELLULAR THERAPY. 2021;27(11):923.e1-923.e12
Allogeneic Transplantation to Treat Therapy-Related Myelodysplastic Syndrome and Acute Myelogenous Leukemia in Adults
Metheny L; Callander NS; Hall AC; Zhang M-J; Bo-Subait K; Wang H-L; Agrawal V; Samer Al-Homsi A; Assal A; Bacher U; Beitinjaneh A; Bejanyan N; Bhatt VR; Bredeson C; Byrne M; Cairo M; Cerny J; DeFilipp Z; Diaz Perez MA; Freytes EO; Ganguly S; Grunwald MR; Hashmi S; Hildebrandt GC; Inamoto Y; Kanakry CG; Kharfan-Dabaja MA; Lazarus HM; Lee JW; Nathan S; Nishihori T; Olsson RF; Ringden O; Rizzieri D; Savani BN; Savoie ML; Seo S; van der Poel M; Verdonck LF; Wagner JL; Yared JA; Hourigan CS; Kebriaei P; Litzow M; Sandmaier BM; Saber W; Weisdorf D; de Lima M
Article: BONE MARROW TRANSPLANTATION. 2021;56(9):2108-2117
Impact of depth of clinical response on outcomes of acute myeloid leukemia patients in first complete remission who undergo allogeneic hematopoietic cell transplantation
Percival M-E; Wang H-L; Zhang M-J; Saber W; de Lima M; Litzow M; Kebriaei P; Abdel-Azim H; Adekola K; Aljurf M; Bacher U; Badawy SM; Beitinjaneh A; Bejanyan N; Bhatt V; Byrne M; Cahn J-Y; Castillo P; Chao N; Chhabra S; Copelan E; Cutler C; DeFilipp Z; Dias A; Diaz MA; Estey E; Farhadfar N; Frangoul HA; Freytes CO; Gale RP; Ganguly S; Gowda L; Grunwald M; Hossain N; Kamble RT; Kanakry CG; Kansagra A; Kharfan-Dabaja MA; Krem M; Lazarus HM; Lee JW; Liesveld JL; Lin R; Liu H; McGuirk J; Munker R; Murthy HS; Nathan S; Nishihori T; Olsson RF; Palmisiano N; Passweg JR; Prestidge T; Ringden O; Rizzieri DA; Rybka WB; Savoie ML; Schultz KR; Seo S; Sharma A; Solh M; Strair R; van der Poel M; Verdonck LF; Yared JA; Weisdorf D; Sandmaier BM
Article: JOURNAL OF CLINICAL ONCOLOGY. 2021;39(21):2397-2409
Impact of Previously Unrecognized HLA Mismatches Using Ultrahigh Resolution Typing in Unrelated Donor Hematopoietic Cell Transplantation
Mayor NP; Wang T; Lee SJ; Kuxhausen M; Vierra-Green C; Barker DJ; Auletta J; Bhatt VR; Gadalla SM; Gragert L; Inamoto Y; Morris GP; Paczesny S; Reshef R; Ringden O; Shaw BE; Shaw P; Spellman SR; Marsh SGE
Article: ORAL DISEASES. 2021;27(5):1217-1225
Oral mucositis after tacrolimus/sirolimus or cyclosporine/methotrexate as graft-versus-host disease prophylaxis
Garming Legert K; Ringden O; Remberger M; Torlen J; Mattsson J; Dahllof G
Article: INTERNATIONAL JOURNAL OF HEMATOLOGY. 2021;113(5):712-722
Cytokine levels following allogeneic hematopoietic cell transplantation: a match-pair analysis of home care versus hospital care
Ringden O; Remberger M; Torlen J; Finnbogadottir S; Svahn B-M; Sadeghi B
Article: FRONTIERS IN IMMUNOLOGY. 2021;12:774052
Expanded Hemodialysis Therapy Ameliorates Uremia-Induced Systemic Microinflammation and Endothelial Dysfunction by Modulating VEGF, TNF-α and AP-1 Signaling
Catar R; Moll G; Kamhieh-Milz J; Luecht C; Chen L; Zhao H; Ernst L; Willy K; Girndt M; Fiedler R; Witowski J; Morawietz H; Ringden O; Dragun D; Eckardt K-U; Schindler R; Zickler D
Article: TRANSPLANTATION AND CELLULAR THERAPY. 2020;26(10):1930-1936
Optimal Donor for African Americans with Hematologic Malignancy: HLA-Haploidentical Relative or Umbilical Cord Blood Transplant
Solomon SR; St Martin A; Zhang M-J; Ballen K; Bashey A; Battiwalla M; Baxter-Lowe LA; Brunstein C; Chhabra S; Diaz Perez MA; Fuchs EJ; Ganguly S; Hardy N; Hematti P; McGuirk J; Peres E; Ringden O; Rizzieri D; Romee R; Solh M; Szwajcer D; van der Poel M; Waller E; William BM; Eapen M
Article: JOURNAL OF CLINICAL ONCOLOGY. 2020;38(18):2062-2076
Composite GRFS and CRFS Outcomes After Adult Alternative Donor HCT
Mehta RS; Holtan SG; Wang T; Hemmer MT; Spellman SR; Arora M; Couriel DR; Alousi AM; Pidala J; Abdel-Azim H; Agrawal V; Ahmed I; Al-Homsi AS; Aljurf M; Antin JH; Askar M; Auletta JJ; Bhatt VR; Chee L; Chhabra S; Daly A; DeFilipp Z; Gajewski J; Gale RP; Gergis U; Hematti P; Hildebrandt GC; Hogan WJ; Inamoto Y; Martino R; Majhail NS; Marks DI; Nishihori T; Olsson RF; Pawarode A; Diaz MA; Prestidge T; Rangarajan HG; Ringden O; Saad A; Savani BN; Schoemans H; Seo S; Schultz KR; Solh M; Spitzer T; Storek J; Teshima T; Verdonck LF; Wirk B; Yared JA; Cahn J-Y; Weisdorf DJ
Article: HAEMATOLOGICA. 2020;105(5):1329-1338
Impact of cytogenetic abnormalities on outcomes of adult Philadelphia-negative acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation: a study by the Acute Leukemia Working Committee of the Center for International Blood and Marrow Transplant Research
Lazaryan A; Dolan M; Zhang M-J; Wang H-L; Kharfan-Dabaja MA; Marks DI; Bejanyan N; Copelan E; Majhail NS; Waller EK; Chao N; Prestidge T; Nishihori T; Kebriaei P; Inamoto Y; Hamilton B; Hashmi SK; Kamble RT; Bacher U; Hildebrandt GC; Stiff PJ; McGuirk J; Aldoss I; Beitinjaneh AM; Muffly L; Vij R; Olsson RF; Byrne M; Schultz KR; Aljurf M; Seftel M; Savoie ML; Savani BN; Verdonck LF; Cairo MS; Hossain N; Bhatt VR; Frangoul HA; Abdel-Azim H; Al Malki M; Munker R; Rizzieri D; Khera N; Nakamura R; Ringden O; van der Poel M; Murthy HS; Liu H; Mori S; De Oliveira S; Bolanos-Meade J; Elsawy M; Barba P; Nathan S; George B; Pawarode A; Grunwald M; Agrawal V; Wang Y; Assal A; Caro PC; Kuwatsuka Y; Seo S; Ustun C; Politikos I; Lazarus HM; Saber W; Sandmaier BM; De Lima M; Litzow M; Bachanova V; Weisdorf D
Article: INTERNATIONAL JOURNAL OF HEMATOLOGY. 2020;111(4):591-594
Treatment of radiculomyelopathy in two patients with placenta-derived decidua stromal cells
Sadeghi B; Ersmark B; Moretti G; Mattsson J; Ringden O
Article: CTS-CLINICAL AND TRANSLATIONAL SCIENCE. 2020;13(2):293-300
Reduced Risk of Sinusoidal Obstruction Syndrome of the Liver after Busulfan-Cyclophosphamide Conditioning Prior to Allogeneic Hematopoietic Stem Cell Transplantation
El-Serafi I; Remberger M; Ringden O; Torlen J; Sundin M; Bjorklund A; Winiarski J; Mattsson J
Article: FRONTIERS IN IMMUNOLOGY. 2020;11:567210
Mesenchymal Stromal Cells in Pediatric Hematopoietic Cell Transplantation a Review and a Pilot Study in Children Treated With Decidua Stromal Cells for Acute Graft-versus-Host Disease
Ringden O; Gustafsson B; Sadeghi B
Article: BLOOD ADVANCES. 2019;3(20):3123-3131
Choice of conditioning regimens for bone marrow transplantation in severe aplastic anemia
Bejanyan N; Kim S; Hebert KM; Kekre N; Abdel-Azim H; Ahmed I; Aljurf M; Badawy SM; Beitinjaneh A; Boelens JJ; Angel Diaz M; Dvorak CC; Gadalla S; Gajewski J; Gale RP; Ganguly S; Gennery AR; George B; Gergis U; Gomez-Almaguer D; Gonzalez Vicent M; Hashem H; Kamble RT; Kasow KA; Lazarus HM; Mathews V; Orchard PJ; Pulsipher M; Ringden O; Schultz K; Teira P; Woolfrey AE; Saldana BD; Savani B; Winiarski J; Yared J; Weisdorf DJ; Antin JH; Eapen M
Article: TRANSPLANTATION AND CELLULAR THERAPY. 2019;25(10):1975-1983
Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Patients Age >69 Years with Acute Myelogenous Leukemia: On Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
Ringden O; Boumendil A; Labopin M; Canaani J; Beelen D; Ehninger G; Niederwieser D; Finke J; Stelljes M; Gerbitz A; Ganser A; Kroeger N; Kantz L; Brecht A; Savani B; Sadeghi B; Mohty M; Nagler A
Article: TRANSPLANTATION AND CELLULAR THERAPY. 2019;25(10):1965-1969
Long-Term Follow-Up of a Pilot Study Using Placenta-Derived Decidua Stromal Cells for Severe Acute Graft-versus-Host Disease
Sadeghi B; Remberger M; Gustafsson B; Winiarski J; Moretti G; Khoein B; Klingspor L; Westgren M; Mattsson J; Ringden O
Article: TRANSPLANTATION AND CELLULAR THERAPY. 2019;25(9):1744-1755
Inferior Outcomes with Cyclosporine and Mycophenolate Mofetil after Myeloablative Allogeneic Hematopoietic Cell Transplantation
Hamilton BK; Liu Y; Hemmer MT; Majhail N; Ringden O; Kim D; Costa L; Stuart R; Alousi A; Pidala JA; Couriel DR; Aljurf M; Antin JH; Bredeson C; Cahn J-Y; Cairo M; Choi SW; Dandoy C; Gale RP; Gergis U; Hematti P; Inamoto Y; Kamble RT; MacMillan M; Marks DI; Nemecek E; Nishihori T; Saad A; Savani BN; Schriber J; Seo S; Socie G; Teshima T; Verdonck LF; Waller EK; Wirk M; Spellman SR; Arora M; Chhabra S
Article: TRANSPLANTATION AND CELLULAR THERAPY. 2019;25(9):1875-1883
Impact of T Cell Dose on Outcome of T Cell-Replete HLA-Matched Allogeneic Peripheral Blood Stem Cell Transplantation
Saad A; Lamb L; Wang T; Hemmer MT; Spellman S; Couriel D; Alousi A; Pidala J; Abdel-Azim H; Agrawall V; Aljurf M; Beitinjaneh AM; Bhatt VR; Buchbinder D; Byrne M; Cahn J-Y; Cairo M; Castillo P; Chhabra S; Angel Diaz M; Farhan S; Floisand Y; Frangoul HA; Gadalla SM; Gajewski J; Gale RP; Gandhi M; Gergis U; Hamilton BK; Hematti P; Hildebrandt GC; Kamble RT; Kanate AS; Khandelwal P; Lazaryn A; MacMillan M; Marks DI; Martino R; Mehta PA; Nishihori T; Olsson RF; Pate SS; Qayed M; Rangarajan HG; Reshef R; Ringden E; Savani BN; Schouten HC; Schultz KR; See S; Shaffer BC; Solh M; Teshima T; Urbano-Ispizua A; Verdonck LF; Vij R; Waller EK; William B; Wirk B; Yared JA; Yu LC; Arora M; Hashmi S
Article: BLOOD ADVANCES. 2019;3(12):1826-1836
Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission
Rashidi A; Hamadani M; Zhang M-J; Wang H-L; Abdel-Azim H; Aljurf M; Assal A; Bajel A; Bashey A; Battiwalla M; Beitinjaneh AM; Bejanyan N; Bhatt VR; Bolanos-Meade J; Byrne M; Cahn J-Y; Cairo M; Ciurea S; Copelan E; Cutler C; Daly A; Diaz M-A; Farhadfar N; Gale RP; Ganguly S; Grunwald MR; Hahn T; Hashmi S; Hildebrandt GC; Holland HK; Hossain N; Kanakry CG; Kharfan-Dabaja MA; Khera N; Koc Y; Lazarus HM; Lee J-W; Maertens J; Martino R; McGuirk J; Munker R; Murthy HS; Nakamura R; Nathan S; Nishihori T; Palmisiano N; Patel S; Pidala J; Olin R; Olsson RF; Oran B; Ringden O; Rizzieri D; Rowe J; Savoie ML; Schultz KR; Seo S; Shaffer BC; Singh A; Solh M; Stockerl-Goldstein K; Verdonck LF; Wagner J; Waller EK; De Lima M; Sandmaier BM; Litzow M; Weisdorf D; Romee R; Saber W
Article: CLINICAL TRANSPLANTATION. 2019;33(6):e13537
The importance of graft cell composition in outcome after allogeneic stem cell transplantation in patients with malignant disease
Svenberg P; Wang T; Uhlin M; Watz E; Remberger M; Ringden O; Mattsson J; Uzunel M
Article: TRANSPLANTATION. 2019;103(6):1247-1252
The Outcome of Allogeneic Hematopoietic Stem Cell Transplantation for Inherited Diseases Is Influenced by HLA Match, Year of Transplantation, and Immunized Female Donor
Ringden O; Remberger M; Gustafsson B; Moretti G; Mattsson J; Winiarski J; Sadeghi B
Article: BLOOD ADVANCES. 2019;3(9):1441-1449
GRFS and CRFS in alternative donor hematopoietic cell transplantation for pediatric patients with acute leukemia
Mehta RS; Holtan SG; Wang T; Hemmer MT; Spellman SR; Arora M; Couriel DR; Alousi AM; Pidala J; Abdel-Azim H; Ahmed I; Aljurf M; Askar M; Auletta JJ; Bhatt V; Bredeson C; Chhabra S; Gadalla S; Gajewski J; Gale RP; Gergis U; Hematti P; Hildebrandt GC; Inamoto Y; Kitko C; Khandelwal P; MacMillan ML; Majhail N; Marks DI; Mehta P; Nishihori T; Olsson RF; Pawarode A; Diaz MA; Prestidge T; Qayed M; Rangarajan H; Ringden O; Saad A; Savani BN; Seo S; Shah A; Shah N; Schultz KR; Solh M; Spitzer T; Szer J; Teshima T; Verdonck LF; Williams KM; Wirk B; Wagner J; Yared JA; Weisdorf DJ
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2019;184(5):782-787
Prophylactic donor lymphocyte infusion after allogeneic stem cell transplantation in acute leukaemia - a matched pair analysis by the Acute Leukaemia Working Party of EBMT
Schmid C; Labopin M; Schaap N; Veelken H; Schleuning M; Stadler M; Finke J; Hurst E; Baron F; Ringden O; Bug G; Blaise D; Tischer J; Bloor A; Esteve J; Giebel S; Savani B; Gorin N-C; Ciceri F; Mohty M; Nagler A
Article: TRANSPLANTATION AND CELLULAR THERAPY. 2019;25(2):270-278
Peripheral Blood versus Bone Marrow from Unrelated Donors: Bone Marrow Allografts Have Improved Long-Term Overall and Graft-versus-Host Disease-Free, Relapse-Free Survival
Alousi A; Wang T; Hemmer MT; Spellman SR; Arora M; Couriel DR; Pidala J; Anderlini P; Boyiadzis M; Bredeson CN; Cahn J-Y; Cairo MS; Gadalla SM; Hashmi SK; Gale RP; Kanda J; Kamble RT; Kharfan-Dabaja MA; Litzow MR; Ringden O; Saad AA; Schultz KR; Verdonck LF; Waller EK; Yared JA; Holtan SG; Weisdorf DJ
Article: TRANSPLANTATION AND CELLULAR THERAPY. 2019;25(2):362-368
Characteristics of Late Fatal Infections after Allogeneic Hematopoietic Cell Transplantation
Norkin M; Shaw BE; Brazauskas R; Tecca HR; Leather HL; Gea-Banacloche J; Kamble RT; DeFilipp Z; Jacobsohn DA; Ringden O; Inamoto Y; Kasow KA; Buchbinder D; Shaw P; Hematti P; Schears R; Badawy SM; Lazarus HM; Bhatt N; Horn B; Chhabra S; Page KM; Hamilton B; Hildebrandt GC; Yared JA; Agrawal V; Beitinjaneh AM; Majhai N; Kindwall-Keller T; Olsson RF; Schoemans H; Gale RP; Ganguly S; Ahmed IA; Schouten HC; Liesveld JL; Khera N; Steinberg A; Shah AJ; Solh M; Marks DI; Rybka W; Aljurf M; Dietz AC; Gergis U; George B; Seo S; Flowers MED; Battiwalla M; Savani BN; Riches ML; Wingard JR
Article: FRONTIERS IN IMMUNOLOGY. 2019;10:2685
Preclinical Toxicity Evaluation of Clinical Grade Placenta-Derived Decidua Stromal Cells
Sadeghi B; Moretti G; Arnberg F; Samen E; Kohein B; Catar R; Kamhieh-Milz J; Geissler S; Moll G; Holmin S; Ringden O
Article: TRANSPLANTATION AND CELLULAR THERAPY. 2019;25(1):73-85
Comparative Analysis of Calcineurin Inhibitor-Based Methotrexate and Mycophenolate Mofetil-Containing Regimens for Prevention of Graft-versus-Host Disease after Reduced-Intensity Conditioning Allogeneic Transplantation
Chhabra S; Liu Y; Hemmer MT; Costa L; Pidala JA; Courie DR; Alousi AM; Majhai NS; Stuart RK; Kim D; Ringden O; Urbano-Ispizua A; Saad A; Savani BN; Cooper B; Marks DI; Socie G; Schouten HC; Schoemans H; Abdel-Azim H; Yared J; Cahn J-Y; Wagner J; Antin JH; Verdonck LF; Lehmann L; Aljurf MD; MacMillan ML; Litzow MR; Solh MM; Qayed M; Hematti P; Kamble RT; Vij R; Hayashi R; Gale RP; Martino R; Seo S; Hashmi SK; Nishihori T; Teshima T; Gergis U; Inamoto Y; Spellman SR; Arora M; Hamilton BK
Article: BLOOD ADVANCES. 2018;2(21):2922-2936
Myeloablative vs reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chronic myeloid leukemia
Chhabra S; Ahn KW; Hu Z-H; Jain S; Assal A; Cerny J; Copelan EA; Daly A; DeFilipp Z; Gadalla SM; Gale RP; Ganguly S; Hamilton BK; Hildebrandt GC; Hsu JW; Inamoto Y; Kanate AS; Khoury HJ; Lazarus HM; Litzow MR; Nathan S; Olsson RF; Pawarode A; Ringden O; Rowe JM; Saad A; Savani BN; Schouten HC; Seo S; Shah NN; Solh M; Stuart RK; Ustun C; Woolfrey AE; Yared JA; Alyea EP; Kalaycio ME; Popat U; Sobecks RM; Saber W
Article: EUROPEAN JOURNAL OF CANCER. 2018;96:73-81
Comparable results of autologous and allogeneic haematopoietic stem cell transplantation for adults with Philadelphia-positive acute lymphoblastic leukaemia in first complete molecular remission: An analysis by the Acute Leukemia Working Party of the EBMT
Giebel S; Labopin M; Potter M; Poire X; Sengeloev H; Socie G; Huynh A; Afanasyev BV; Schanz U; Ringden O; Kalhs P; Beelen DW; Campos AM; Masszi T; Canaani J; Mohty M; Nagler A
Article: BLOOD ADVANCES. 2018;2(9):1022-1031
Graft-versus-host disease in recipients of male unrelated donor compared with parous female sibling donor transplants
Kumar AJ; Kim S; Hemmer MT; Arora M; Spellman SR; Pidala JA; Couriel DR; Alousi AM; Aljurf MD; Cahn J-Y; Cairo MS; Cutler CS; Farhan S; Gergis U; Hale GA; Hashmi SK; Inamoto Y; Kamble RT; Kharfan-Dabaja MA; MacMillan ML; Marks DI; Nakasone H; Norkin M; Qayed M; Ringden O; Schouten HC; Schultz KR; Solh MM; Teshima T; Urbano-Ispizua A; Verdonck LF; Gale RP; Hamilton BK; Majhail NS; Loren AW
Article: MEDICAL ONCOLOGY. 2018;35(6):79
Reduced intensity conditioning increases risk of severe cGVHD: identification of risk factors for cGVHD in a multicenter setting
Afram G; Perez-Simon JA; Remberger M; Caballero-Velazquez T; Martino R; Luis Pinana J; Ringden O; Esquirol A; Lopez-Corral L; Garcia I; Lopez-Godino O; Sierra J; Caballero D; Ljungman P; Vazquez L; Hagglund H
Article: INTERNATIONAL JOURNAL OF HEMATOLOGY. 2018;107(4):478-485
Long-term outcome in patients treated at home during the pancytopenic phase after allogeneic haematopoietic stem cell transplantation
Ringden O; Sadeghi B; Moretti G; Finnbogadottir S; Eriksson B; Mattsson J; Svahn B-M; Remberger M
Article: NEPHROLOGY DIALYSIS TRANSPLANTATION. 2018;33(4):574-585
Tumour necrosis factor-alpha in uraemic serum promotes osteoblastic transition and calcification of vascular smooth muscle cells via extracellular signal-regulated kinases and activator protein 1/c-FOS-mediated induction of interleukin 6 expression
Zickler D; Luecht C; Willy K; Chen L; Witowski J; Girndt M; Fiedler R; Storr M; Kamhieh-Milz J; Schoon J; Geissler S; Ringden O; Schindler R; Moll G; Dragun D; Catar R
Article: STEM CELLS TRANSLATIONAL MEDICINE. 2018;7(4):325-331
Placenta-Derived Decidua Stromal Cells for Treatment of Severe Acute Graft-Versus-Host Disease
Ringden O; Baygan A; Remberger M; Gustafsson B; Winiarski J; Khoein B; Moll G; Klingspor L; Westgren M; Sadeghi B
Article: TRANSPLANTATION AND CELLULAR THERAPY. 2018;24(3):521-528
Influence of Age on Acute and Chronic GVHD in Children Undergoing HLA-Identical Sibling Bone Marrow Transplantation for Acute Leukemia: Implications for Prophylaxis
Qayed M; Wang T; Hemmer MT; Spellman S; Arora M; Couriel D; Alousi A; Pidala J; Abdel-Azim H; Aljurf M; Ayas M; Bitan M; Cairo M; Choi SW; Dandoy C; Delgado D; Gale RP; Hale G; Frangoul H; Kamble RT; Kharfan-Dabaja M; Lehman L; Levine J; MacMillan M; Marks DI; Nishihori T; Olsson RF; Hematti P; Ringden O; Saad A; Satwani P; Savani BN; Schultz KR; Seo S; Shenoy S; Waller EK; Yu L; Horowitz MM; Horan J
Article: BONE MARROW TRANSPLANTATION. 2018;53(2):213-218
Impact of HLA-G polymorphism on the outcome of allogeneic hematopoietic stem cell transplantation for metastatic renal cell carcinoma
Crocchiolo R; Ringden O; Bay J-O; Blaise D; Omasic B; Mazzi B; Picard C; Trinca S; Barkholt L; Peccatori J; Gregori S; Amodio G; Fleischhauer K; Ciceri F; Bregni M
Article: JOURNAL OF INTERNAL MEDICINE. 2018;283(2):166-177
What is the outcome in patients with acute leukaemia who survive severe acute graft-versus-host disease?
Ringden O; Labopi M; Sadeghi B; Mailhol A; Beelen D; Floisand Y; Ghavamzadeh A; Finke J; Ehninger G; Volin L; Socie G; Kroeger N; Stuhler G; Ganser A; Schmid C; Giebel S; Mohty M; Nagler A
Article: FRONTIERS IN IMMUNOLOGY. 2018;9:760
Cytomegalovirus-Specific CD8+T-Cells With Different T-Cell Receptor Affinities Segregate T-Cell Phenotypes and Correlate With Chronic Graft-Versus-Host Disease in Patients Post-Hematopoietic Stem Cell Transplantation
Poiret T; Axelsson-Robertson R; Remberger M; Luo X-H; Rao M; Nagchowdhury A; Von Landenberg A; Ernberg I; Ringden O; Maeurer M
Article: ACTA HAEMATOLOGICA. 2018;139(2):106-114
Placenta-Derived Decidua Stromal Cells for Hemorrhagic Cystitis after Stem Cell Transplantation
Aronsson-Kurttila W; Baygan A; Moretti G; Remberger M; Khoein B; Moll G; Sadeghi B; Ringden O
Article: PEDIATRIC TRANSPLANTATION. 2017;21(5)
Successful treatment with placenta-derived decidual stromal cells in a pediatric patient with life-threatening acute gastrointestinal graft-versus-host disease
Gustafsson B; Frisk P; Szakos A; Sadeghi B; Ringden O; Frost B-M
Article: TRANSPLANTATION AND CELLULAR THERAPY. 2017;23(8):1327-1334
Survival and Late Effects after Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancy at Less than Three Years of Age
Vrooman LM; Millard HR; Brazauskas R; Majhail NS; Battiwalla M; Flowers ME; Savani BN; Akpek G; Aljurf M; Bajwa R; Baker KS; Beitinjaneh A; Bitan M; Buchbinder D; Chow E; Dandoy C; Dietz AC; Diller L; Gale RP; Hashmi SK; Hayashi R; Hematti P; Kamble RTF; Kasow KA; Kletzel M; Lazarus HM; Malone AK; Marks DI; O'Brien TA; Olsson RF; Ringden O; Seo S; Steinberg A; Yu LC; Warwick A; Shaw B; Duncan C
Article: JOURNAL OF IMMUNOTHERAPY. 2017;40(4):132-139
A Preliminary Report: Radical Surgery and Stem Cell Transplantation for the Treatment of Patients With Pancreatic Cancer
Omazic B; Ayoglu B; Lohr M; Segersvard R; Verbeke C; Magalhaes I; Potacova Z; Mattsson J; Terman A; Ghazi S; Albiin N; Kartalis N; Nilsson P; Poiret T; Liu Z; Heuchel R; Schwenk JM; Permert J; Maeurer MJ; Ringden O
Article: JOURNAL OF LEUKOCYTE BIOLOGY. 2017;101(3):623-632
Frontline Science: Placenta-derived decidual stromal cells alter IL-2R expression and signaling in alloantigen-activated T cells
Erkers T; Solders M; Verleng L; Bergstroem C; Stikvoort A; Rane L; Nava S; Ringden O; Kaipe H
Article: BONE MARROW TRANSPLANTATION. 2017;52(3):400-408
GvHD after umbilical cord blood transplantation for acute leukemia: an analysis of risk factors and effect on outcomes
Chen Y-B; Wang T; Hemmer MT; Brady C; Couriel DR; Alousi A; Pidala J; Urbano-Ispizua A; Choi SW; Nishihori T; Teshima T; Inamoto Y; Wirk B; Marks DI; Abdel-Azim H; Lehmann L; Yu L; Bitan M; Cairo MS; Qayed M; Salit R; Gale RP; Martino R; Jaglowski S; Bajel A; Savani B; Frangoul H; Lewis ID; Storek J; Askar M; Kharfan-Dabaja MA; Aljurf M; Ringden O; Reshef R; Olsson RF; Hashmi S; Seo S; Spitzer TR; MacMillan ML; Lazaryan A; Spellman SR; Arora M; Cutler CS
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2017;176(3):431-439
Sequential chemotherapy followed by reduced-intensity conditioning and allogeneic haematopoietic stem cell transplantation in adult patients with relapse or refractory acute myeloid leukaemia: a survey from the Acute Leukaemia Working Party of EBMT
Ringden O; Labopin M; Schmid C; Sadeghi B; Polge E; Tischer J; Ganser A; Michallet M; Kanz L; Schwerdtfeger R; Nagler A; Mohty M
Article: FRONTIERS IN IMMUNOLOGY. 2017;8:795
Safety and Side Effects of Using Placenta-Derived Decidual Stromal Cells for Graft-versus-Host Disease and Hemorrhagic Cystitis
Baygan A; Aronsson-Kurttila W; Moretti G; Tibert B; Dahllof G; Klingspor L; Gustafsson B; Khoein B; Moll G; Hausmann C; Svahn B-M; Westgren M; Remberger M; Sadeghi B; Ringden O
Article: AMERICAN JOURNAL OF HEMATOLOGY. 2017;92(1):42-49
Reduced intensity conditioned allograft yields favorable survival for older adults with B-cell acute lymphoblastic leukemia
Rosko AE; Wang H-L; de Lima M; Sandmaier B; Khoury HJ; Artz A; Brammer J; Bredeson C; Farag S; Kharfan-Dabaja M; Lazarus HM; Marks DI; Bufarull RM; McGuirk J; Mohty M; Nishihori T; Nivison-Smith I; Rashidi A; Ringden O; Seftel M; Weisdorf D; Bachanova V; Saber W
Article: DERMATOLOGY. 2017;233(4):303-313
Photochemotherapy and Graft-versus-Leukemia Reaction in Acute Leukemia: Tumor Immunity and Survival Are Dependent on Timing of Photochemotherapy of the Skin
Feldreich N; Ringden O; Emtestam L
Article: HAEMATOLOGICA. 2016;101(11):1417-1425
A prospective randomized trial comparing cyclosporine/methotrexate and tacrolimus/sirolimus as graft-versus-host disease prophylaxis after allogeneic hematopoietic stem cell transplantation
Torlen J; Ringden O; Garming-Legert K; Ljungman P; Winiarski J; Remes K; Itala-Remes M; Remberger M; Mattsson J
Article: HAEMATOLOGICA. 2016;101(11):1426-1433
The prognostic value of serum C-reactive protein, ferritin, and albumin prior to allogeneic transplantation for acute myeloid leukemia and myelodysplastic syndromes
Artz AS; Logan B; Zhu X; Akpek G; Martino Bufarull R; Gupta V; Lazarus HM; Litzow M; Loren A; Majhail NS; Maziarz RHT; McCarthy P; Popat U; Saber W; Spellman S; Ringden O; Wickrema A; Pasquini MC; Cooke KR
Article: PEDIATRIC TRANSPLANTATION. 2016;20(5):667-674
Improved overall survival for pediatric patients undergoing allogeneic hematopoietic stem cell transplantation - A comparison of the last two decades
Svenberg P; Remberger M; Uzunel M; Mattsson J; Gustafsson B; Fjaertoft G; Sundin M; Winiarski J; Ringden O
Article: TRANSPLANTATION. 2016;100(6):1356-1362
Allogeneic Hematopoietic Stem Cell Transplantation in the Treatment of Human C1q Deficiency: The Karolinska Experience
Olsson RF; Hagelberg S; Schiller B; Ringden O; Truedsson L; Ahlin A
Article: ONCOTARGET. 2016;7(21):30230-30240
Both high and low levels of cellular Epstein-Barr virus DNA in blood identify failure after hematologic stem cell transplantation in conjunction with acute GVHD and type of conditioning
Li Q; Rane L; Poiret T; Zou J; Magalhaes I; Ahmed R; Du Z; Vudattu N; Meng Q; Gustafsson-Jernberg A; Winiarski J; Ringden O; Maeurer M; Remberger M; Ernberg I
Article: TRANSPLANTATION AND CELLULAR THERAPY. 2016;22(4):676-681
Long-Term Follow-Up of Allogeneic Hematopoietic Stem Cell Transplantation for Solid Cancer
Omazic B; Remberger M; Barkholt L; Soderdahl G; Potacova Z; Wersall P; Ericzon B-G; Mattsson J; Ringden O
Article: TRANSPLANTATION AND CELLULAR THERAPY. 2016;22(2):248-257
Hematopoietic Cell Transplantation Outcomes in Monosomal Karyotype Myeloid Malignancies
Pasquini MC; Zhang M-J; Medeiros BC; Armand P; Hui Z-H; Nishihori T; Aljurf MD; Akpek G; Cahn J-Y; Cairo MS; Cerny J; Copelan EA; Deol A; Freytes CO; Gale RP; Ganguly S; George B; Gupta V; Hale GA; Kamble RT; Klumpp TR; Lazarus HM; Luger SM; Liesveld JL; Litzow MR; Marks DI; Martino R; Norkin M; Olsson RF; Oran B; Pawarode A; Pulsipher MA; Ramanathan M; Reshef R; Saad AA; Saber W; Savani BN; Schouten HC; Ringden O; Tallman MS; Uy GL; Wood WAJ; Wirk B; Perez WS; Batiwalla M; Weisdorf DJ
Article: LEUKEMIA. 2016;30(2):447-455
Is there a stronger graft-versus-leukemia effect using HLA-haploidentical donors compared with HLA-identical siblings?
Ringden O; Labopin M; Ciceri F; Velardi A; Bacigalupo A; Arcese W; Ghavamzadeh A; Hamladji RM; Schmid C; Nagler A; Mohty M
Article: CELL BIOLOGY AND TRANSLATIONAL MEDICINE, VOL 14: STEM CELLS IN LINEAGE SPECIFIC DIFFERENTIATION AND DISEASE. 2016;951:77-98
Cryopreserved or Fresh Mesenchymal Stromal Cells: Only a Matter of Taste or Key to Unleash the Full Clinical Potential of MSC Therapy?
Moll G; Geissler S; Catar R; Ignatowicz L; Hoogduijn MJ; Strunk D; Bieback K; Ringden O
Article: DERMATOLOGY. 2016;232(4):453-463
Photochemotherapy of Cutaneous Graft-versus-Host Disease May Reduce Concomitant Visceral Disease
Feldreich N; Ringden O; Emtestam L; Omazic B
Article: CELL TRANSPLANTATION. 2016;25(2):401-410
Intra-arterial Administration of Placenta-Derived Decidual Stromal Cells to the Superior Mesenteric Artery in the Rabbit: Distribution of Cells, Feasibility, and Safety
Arnberg F; Lundberg J; Olsson A; Samen E; Jaff N; Jussing E; Dahlen U; Nava S; Axelsson R; Ringden O; Kaipe H; Holmin S
Article: CYTOTHERAPY. 2015;17(12):1732-1745
Xeno-immunosuppressive properties of human decidual stromal cells in mouse models of alloreactivity in vitro and in vivo
Sadeghi B; Heshmati Y; Khoein B; Kaipe H; Uzunel M; Walfridsson J; Ringden O
Article: STEM CELLS AND DEVELOPMENT. 2015;24(19):2269-2279
Different Procoagulant Activity of Therapeutic Mesenchymal Stromal Cells Derived from Bone Marrow and Placental Decidua
Moll G; Ignatowicz L; Catar R; Luecht C; Sadeghi B; Hamad O; Jungebluth P; Dragun D; Schmidtchen A; Ringden O
Article: TRANSFUSION. 2015;55(10):2339-2350
Quality of the hematopoietic stem cell graft affects the clinical outcome of allogeneic stem cell transplantation
Watz E; Remberger M; Ringden O; Ljungman P; Sundin M; Mattsson J; Uhlin M
Article: TRANSPLANTATION AND CELLULAR THERAPY. 2015;21(9):1589-1596
Impact of KIR and HLA Genotypes on Outcomes after Reduced-Intensity Conditioning Hematopoietic Cell Transplantation
Sobecks RM; Wang T; Askar M; Gallagher MM; Haagenson M; Spellman S; Fernandez-Vina M; Malmberg K-J; Mueller C; Battiwalla M; Gajewski J; Verneris MR; Ringden O; Marino S; Davies S; Dehn J; Bornhaeuser M; Inamoto Y; Woolfrey A; Shaw P; Pollack M; Weisdorf D; Milller J; Hurley C; Lee SJ; Hsu K
Article: STEM CELLS AND DEVELOPMENT. 2015;24(12):1471-1482
Immunogenicity of Decidual Stromal Cells in an Epidermolysis Bullosa Patient and in Allogeneic Hematopoietic Stem Cell Transplantation Patients
Kaipe H; Carlson L-M; Erkers T; Nava S; Mollden P; Gustafsson B; Qian H; Li X; Hashimoto T; Sadeghi B; Alheim M; Ringden O
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2015;169(5):711-718
Haematopoietic stem cell transplantation for refractory Langerhans cell histiocytosis: outcome by intensity of conditioning
Veys PA; Nanduri V; Baker KS; He W; Bandini G; Biondi A; Dalissier A; Davis JH; Eames GM; Egeler RM; Filipovich AH; Fischer A; Juergens H; Krance R; Lanino E; Leung WH; Matthes S; Michel G; Orchard PJ; Pieczonka A; Ringden O; Schlegel PG; Sirvent A; Vettenranta K; Eapen M
Article: SUPPORTIVE CARE IN CANCER. 2015;23(6):1749-1757
The relationship between oral mucositis and levels of pro-inflammatory cytokines in serum and in gingival crevicular fluid in allogeneic stem cell recipients
Legert KG; Tsilingaridis G; Remberger M; Ringden O; Heimdahl A; Yucel-Lindberg T; Dahllof G
Article: TRANSPLANTATION AND CELLULAR THERAPY. 2015;21(5):889-893
Effect of Total Nucleated and CD34⁺ Cell Dose on Outcome after Allogeneic Hematopoietic Stem Cell Transplantation
Remberger M; Torlen J; Ringden E; Engstrom M; Watz E; Uhlin M; Mattsson J
Article: STEM CELLS AND DEVELOPMENT. 2015;24(2):253-263
Treatment of Severe Chronic Graft-Versus-Host Disease with Decidual Stromal Cells and Tracing with ¹¹¹Indium Radiolabeling
Erkers T; Kaipe H; Nava S; Mollden P; Gustafsson B; Axelsson R; Ringden O
Article: BLOOD. 2014;124(26):3996-4003
HLA-C expression levels define permissible mismatches in hematopoietic cell transplantation
Petersdorf EW; Gooley TA; Malkki M; Bacigalupo AP; Cesbron A; Du Toit E; Ehninger G; Egeland T; Fischer GF; Gervais T; Haagenson MD; Horowitz MM; Hsu K; Jindra P; Madrigal A; Oudshoorn M; Ringden O; Schroeder ML; Spellman SR; Tiercy J-M; Velardi A; Witt CS; O'Huigin C; Apps R; Carrington M
Article: BONE MARROW TRANSPLANTATION. 2014;49(12):1486-1491
Superselective intra-arterial umbilical cord blood administration to BM in experimental animals
Arnberg F; Lundberg J; Kenne E; Jaff N; Mueller P; Nava S; Kaipe H; Ringden O; Holmin S
Article: TRANSPLANTATION AND CELLULAR THERAPY. 2014;20(11):1777-1784
Second Solid Cancers after Allogeneic Hematopoietic Cell Transplantation Using Reduced-Intensity Conditioning
Ringden O; Brazauskas R; Wang Z; Ahmed I; Atsuta Y; Buchbinder D; Burns LJ; Cahn J-Y; Duncan C; Hale GA; Halter J; Hayashi RJ; Hsu JW; Jacobsohn DA; Kamble RT; Kamani NR; Kasow KA; Khera N; Lazarus HM; Loren AW; Marks DI; Myers KC; Ramanathan M; Saber W; Savani BN; Schouten HC; Socie G; Sorror ML; Steinberg A; Popat U; Wingard JR; Mattsson J; Majhail NS
Article: JOURNAL OF IMMUNOTHERAPY. 2014;37(8):416-425
TCR⁺CD4^-CD8^- T cells in Antigen-specific MHC Class I-restricted T-cell Responses After Allogeneic Hematopoietic Stem Cell Transplantation
Ahmed RK; Poiret T; Ambati A; Rane L; Remberger M; Omazic B; Vudattu NK; Winiarski J; Ernberg I; Axelsson-Robertson R; Magalhaes I; Castelli C; Ringden O; Maeurer M
Article: TRANSPLANTATION. 2014;98(5):569-577
Who Is the Best Hematopoietic Stem-Cell Donor for a Male Patient With Acute Leukemia?
Ringden O; Labopin M; Solders M; Beelen D; Arnold R; Ehninger G; Milpied N; Niederwieser D; Hamladji R-M; Kyrcz-Krzemien S; Ganser A; Socie G; Stelljes M; Volin L; Craddock C; Mohty M
Article: TRANSPLANTATION AND CELLULAR THERAPY. 2014;20(9):1418-1425
Low CD34 Dose Is Associated with Poor Survival after Reduced-Intensity Conditioning Allogeneic Transplantation for Acute Myeloid Leukemia and Myelodygplastic Syndrome
Torlen J; Ringden O; Le Rademacher J; Batiwalla M; Chen J; Erkers T; Ho V; Kebriaei P; Keever-Taylor C; Kindwall-Keller T; Lazarus HM; Laughlin MJ; Lill M; O'Brien T; Perales M-A; Rocha V; Savani BN; Szwajcer D; Valcarcel D; Eapen M
Article: BONE MARROW TRANSPLANTATION. 2014;49(8):1046-1051
Hematopoietic SCT: a useful treatment for late metachromatic leukodystrophy
Solders M; Martin DA; Andersson C; Remberger M; Andersson T; Ringden O; Solders G
Article: SUPPORTIVE CARE IN CANCER. 2014;22(8):2133-2140
Reduced intensity conditioning and oral care measures prevent oral mucositis and reduces days of hospitalization in allogeneic stem cell transplantation recipients
Legert KG; Remberger M; Ringden O; Heimdahl A; Dahllof G
Article: ANTIMICROBIAL AGENTS AND CHEMOTHERAPY. 2014;58(8):4941-4943
Posaconazole Concentrations in Human Tissues after Allogeneic Stem Cell Transplantation
Blennow O; Eliasson E; Pettersson T; Pohanka A; Szakos A; El-Serafi I; Hassan M; Ringden O; Mattsson J
Article: BMC IMMUNOLOGY. 2014;15:25
Reduced plasma levels of soluble interleukin-7 receptor during graft-versus-host disease (GVHD) in children and adults
Poiret T; Rane L; Remberger M; Omazic B; Gustafsson-Jernberg A; Vudattu NK; Ahmed R; Ernberg I; Winiarski J; Magalhaes I; Ringden O; Maeurer M
Article: PEDIATRIC TRANSPLANTATION. 2014;18(4):398-404
Home care during neutropenia after allogeneic hematopoietic stem cell transplantation in children and adolescents is safe and may be more advantageous than isolation in hospital
Ringden O; Remberger M; Torlen J; Engstrom M; Fjaertoft G; Mattsson J; Svahn B-M
Article: HAEMATOLOGICA. 2014;99(2):346-352
Risk factors for Epstein-Barr virus-related post-transplant lymphoproliferative disease after allogeneic hematopoietic stem cell transplantation
Uhlin M; Wikell H; Sundin M; Blennow O; Maeurer M; Ringden O; Winiarski J; Ljungman P; Remberger M; Mattsson J
Article: TRANSPLANTATION AND CELLULAR THERAPY. 2014;20(2):264-271
Analysis of Donor and Recipient ABO Incompatibility and Antibody-Associated Complications after Allogeneic Stem Cell Transplantation with Reduced-Intensity Conditioning
Watz E; Remberger M; Ringden E; Lundahl J; Ljungman P; Mattsson J; Wikman A; Uhlin M
Article: TRANSPLANTATION AND CELLULAR THERAPY. 2014;20(2):202-208
Effect of Postremission Therapy before Reduced-Intensity Conditioning Allogeneic Transplantation for Acute Myeloid Leukemia in First Complete Remission
Warlick ED; Paulson K; Brazauskas R; Zhong X; Miller AM; Camitta BM; George B; Savani BN; Ustun C; Marks DI; Waller EK; Baron F; Freytes CO; Socie G; Akpek G; Schouten HC; Lazarus HM; Horwitz EM; Koreth J; Cahn J-Y; Bornhauser M; Seftel M; Cairo MS; Laughlin MJ; Sabloff M; Ringden O; Gale RP; Kamble RT; Vij R; Gergis U; Mathews V; Saber W; Chen Y-B; Liesveld JL; Cutler CS; Ghobadi A; Uy GL; Eapen M; Weisdorf DJ; Litzow MR
Article: BONE MARROW TRANSPLANTATION. 2014;49(2):168-173
Prophylaxis and treatment of GVHD: EBMT-ELN working group recommendations for a standardized practice
Ruutu T; Gratwohl A; de Witte T; Afanasyev B; Apperley J; Bacigalupo A; Dazzi F; Dreger P; Duarte R; Finke J; Garderet L; Greinix H; Holler E; Kroeger N; Lawitschka A; Mohty M; Nagler A; Passweg J; Ringden O; Socie G; Sierra J; Sureda A; Wiktor-Jedrzejczak W; Madrigal A; Niederwieser D
Article: TRANSPLANTATION AND CELLULAR THERAPY. 2014;20(1):135-138
Improved survival with ursodeoxycholic acid prophylaxis in allogeneic stem cell transplantation: long-term follow-up of a randomized study.
Ruutu T; Juvonen E; Remberger M; Remes K; Volin L; Mattsson J; Nihtinen A; Hägglund H; Ringdén O; Nordic Group for Blood and Marrow Transplantation
Article: BLOOD. 2013;122(22):3651-3658
Amino acid substitution at peptide-binding pockets of HLA class I molecules increases risk of severe acute GVHD and mortality
Pidala J; Wang T; Haagenson M; Spellman SR; Askar M; Battiwalla M; Baxter-Lowe LA; Bitan M; Fernandez-Vina M; Gandhi M; Jakubowski AA; Maiers M; Marino SR; Marsh SGE; Oudshoorn M; Palmer J; Prasad VK; Reddy V; Ringden O; Saber W; Santarone S; Schultz KR; Setterholm M; Trachtenberg E; Turner EV; Woolfrey AE; Lee SJ; Anasetti C
Article: ACTA PAEDIATRICA. 2013;102(11):1087-1094
Chronic granulomatous disease - haematopoietic stem cell transplantation versus conventional treatment
Ahlin A; Fugelang J; de Boer M; Ringden O; Fasth A; Winiarski J
Article: STEM CELLS AND DEVELOPMENT. 2013;22(19):2596-2605
Decidual Stromal Cells Promote Regulatory T Cells and Suppress Alloreactivity in a Cell Contact-Dependent Manner
Erkers T; Nava S; Yosef J; Ringden O; Kaipe H
Article: STEM CELLS. 2013;31(8):1715-1725
Alterations in the Cellular Immune Compartment of Patients Treated with Third-Party Mesenchymal Stromal Cells Following Allogeneic Hematopoietic Stem Cell Transplantation
Jitschin R; Mougiakakos D; Von Bahr L; Voelkl S; Moll G; Ringden O; Kiessling R; Linder S; Le Blanc K
Article: JOURNAL OF INTERNAL MEDICINE. 2013;274(2):153-162
A prospective randomized toxicity study to compare reduced-intensity and myeloablative conditioning in patients with myeloid leukaemia undergoing allogeneic haematopoietic stem cell transplantation
Ringden O; Erkers T; Aschan J; Garming-Legert K; Le Blanc K; Hagglund H; Omazic B; Svenberg P; Dahllof G; Mattsson J; Ljungman P; Remberger M
Article: CLINICAL TRANSPLANTATION. 2013;27(4):E368-E374
A high antithymocyte globulin dose increases the risk of relapse after reduced intensity conditioning HSCT with unrelated donors
Remberger M; Ringden O; Hagglund H; Svahn B-M; Ljungman P; Uhlin M; Mattsson J
Article: BONE MARROW TRANSPLANTATION. 2013;48(6):825-831
Effects of spleen status on early outcomes after hematopoietic cell transplantation
Akpek G; Pasquini MC; Logan B; Agovi M-A; Lazarus HM; Marks DI; Bornhaeueser M; Ringden O; Maziarz RT; Gupta V; Popat U; Maharaj D; Bolwell BJ; Rizzo JD; Ballen KK; Cooke KR; McCarthy PL; Ho VT
Article: PEDIATRIC TRANSPLANTATION. 2013;17(3):285-293
Increased risk of gastrointestinal acute GVHD following the addition of melphalan to busulfan/cyclophosphamide conditioning
Martensson T; Priftakis P; Casswall T; Ringden O; Mattsson J; Remberger M; Hassan M; Gustafsson B
Article: BONE MARROW TRANSPLANTATION. 2013;48(4):537-543
Graft failure in the modern era of allogeneic hematopoietic SCT
Olsson R; Remberger M; Schaffer M; Berggren DM; Svahn B-M; Mattsson J; Ringden O
Article: STEM CELLS. 2013;31(3):592-601
Fetal Membrane Cells for Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease
Ringden O; Erkers T; Nava S; Uzunel M; Iwarsson E; Conrad R; Westgren M; Mattsson J; Kaipe H
Article: TRANSPLANTATION AND CELLULAR THERAPY. 2013;19(2):314-320
Many Days at Home during Neutropenia after Allogeneic Hematopoietic Stem Cell Transplantation Correlates with Low Incidence of Acute Graft-versus-Host Disease
Ringden O; Remberger M; Holmberg K; Edeskog C; Wikstrom M; Eriksson B; Finnbogadottir S; Fransson K; Milovsavljevic R; Omazic B; Svenberg P; Mattsson J; Svahn B-M
Article: MEDICAL ONCOLOGY. 2012;29(4):2348-2358
Different impact of intermediate and unfavourable cytogenetics at the time of diagnosis on outcome of de novo AML after allo-SCT: a long-term retrospective analysis from a single institution
Nahi H; Remberger M; Machaczka M; Ungerstedt J; Mattson J; Ringden O; Le-Blanc K; Ljungman P; Hagglund H
Article: TRANSPLANTATION. 2012;94(10):1066-1074
Factors With an Impact on Chimerism Development and Long-Term Survival After Umbilical Cord Blood Transplantation
Berglund S; Le Blanc K; Remberger M; Gertow J; Uzunel M; Svenberg P; Winiarski J; Ljungman P; Ringden O; Uhlin M; Mattsson J
Article: JOURNAL OF INTERNAL MEDICINE. 2012;272(5):472-483
Bone marrow or peripheral blood stem cell transplantation from unrelated donors in adult patients with acute myeloid leukaemia, an Acute Leukaemia Working Party analysis in 2262 patients
Ringden O; Labopin M; Beelen DW; Volin L; Ehninger G; Finke J; Greinix HT; Kyrcz-Krzemien S; Bunjes D; Brinch L; Niederwieser D; Arnold R; Mohty M; Rocha V
Article: TRANSPLANTATION AND CELLULAR THERAPY. 2012;18(9):1438-1445
Long-Term Survival and Late Deaths after Hematopoietic Cell Transplantation for Primary Immunodeficiency Diseases and Inborn Errors of Metabolism
Eapen M; Ahn KW; Orchard PJ; Cowan MJ; Davies SM; Fasth A; Hassebroek A; Ayas M; Bonfim C; O'Brien TA; Gross TG; Horwitz M; Horwitz E; Kapoor N; Kurtzberg J; Majhail N; Ringden O; Szabolcs P; Veys P; Baker KS
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 2012;89(3):220-227
Treatment with mesenchymal stromal cells is a risk factor for pneumonia-related death after allogeneic hematopoietic stem cell transplantation
Forslow U; Blennow O; LeBlanc K; Ringden O; Gustafsson B; Mattsson J; Remberger M
Article: HAEMATOLOGICA. 2012;97(8):1187-1195
Evaluation of prognostic factors among patients with chronic graft-versus-host disease
Perez-Simon JA; Afram G; Martino R; Pinana JL; Caballero-Velazquez T; Ringden O; Valcarcel D; Caballero D; Remberger M; de Paz Y; Sierra J; San Miguel J; Hagglund H
Article: STEM CELLS. 2012;30(7):1575-1578
Analysis of Tissues Following Mesenchymal Stromal Cell Therapy in Humans Indicates Limited Long-Term Engraftment and No Ectopic Tissue Formation
von Bahr L; Batsis I; Moll G; Hagg M; Szakos A; Sundberg B; Uzunel M; Ringden O; Le Blanc K
Article: STEM CELLS. 2012;30(7):1565-1574
Are Therapeutic Human Mesenchymal Stromal Cells Compatible with Human Blood?
Moll G; Rasmusson-Duprez I; von Bahr L; Connolly-andersen A-M; Elgue G; Funke L; Hamad OA; Lonnies H; Magnusson PU; Sanchez J; Teramura Y; Nilsson-Ekdahl K; Ringden O; Korsgren O; Nilsson B; Le Blanc K
Article: STEM CELLS AND DEVELOPMENT. 2012;21(9):1409-1417
Mesenchymal Stem Cells Inhibit Thymic Reconstitution After Allogeneic Cord Blood Transplantation
Uhlin M; Sairafi D; Berglund S; Thunberg S; Gertow J; Ringden O; Uzunel M; Remberger M; Mattsson J
Article: BONE MARROW TRANSPLANTATION. 2012;47(6):831-837
Effect of acute and chronic GVHD on relapse and survival after reduced-intensity conditioning allogeneic transplantation for myeloma
Ringden O; Shrestha S; da Silva GT; Zhang M-J; Dispenzieri A; Remberger M; Kamble R; Freytes CO; Gale RP; Gibson J; Gupta V; Holmberg L; Lazarus H; McCarthy P; Meehan K; Schouten H; Milone GA; Lonial S; Hari PN
Article: BONE MARROW TRANSPLANTATION. 2012;47(5):706-715
Increased costs after allogeneic haematopoietic SCT are associated with major complications and re-transplantation
Svahn B-M; Remberger M; Alvin O; Karlsson H; Ringden O
Article: TRANSPLANTATION AND CELLULAR THERAPY. 2012;18(4):557-564
Long-Term Complications, Immunologic Effects, and Role of Passage for Outcome in Mesenchymal Stromal Cell Therapy
von Bahr L; Sundberg B; Lonnies L; Sander B; Karbach H; Hagglund H; Ljungman P; Gustafsson B; Karlsson H; Le Blanc K; Ringden O
Article: LANCET ONCOLOGY. 2012;13(4):366-374
Effect of T-cell-epitope matching at HLA-DPB1 in recipients of unrelated-donor haemopoietic-cell transplantation: a retrospective study
Fleischhauer K; Shaw BE; Gooley T; Malkki M; Bardy P; Bignon J-D; Dubois V; Horowitz MM; Madrigal JA; Morishima Y; Oudshoorn M; Ringden O; Spellman S; Velardi A; Zino E; Petersdorf EW
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2012;157(2):220-229
Growth factor-associated graft-versus-host disease and mortality 10 years after allogeneic bone marrow transplantation
Ringden O; Labopin M; Gorin N-C; Volin L; Torelli GF; Attal M; Jouet JP; Milpied N; Socie G; Cordonnier C; Michallet M; Atienza AI; Hermine O; Mohty M
Article: BONE MARROW TRANSPLANTATION. 2012;47(3):404-410
Salivary secretion in children after fractionated or single-dose TBI
Legert KG; Remberger M; Ringden O; Heimdahl A; Dahllof G
Article: BONE MARROW TRANSPLANTATION. 2012;47(2):203-211
Similar outcomes using myeloablative vs reduced-intensity allogeneic transplant preparative regimens for AML or MDS
Luger SM; Ringden O; Zhang M-J; Perez WS; Bishop MR; Bornhauser M; Bredeson CN; Cairo MS; Copelan EA; Gale RP; Giralt SA; Gulbas Z; Gupta V; Hale GA; Lazarus HM; Lewis VA; Lill MC; McCarthy PL; Weisdorf DJ; Pulsipher MA
Article: ORTHODONTICS & CRANIOFACIAL RESEARCH. 2012;15(1):21-29
Disturbances in dental development and craniofacial growth in children treated with hematopoietic stem cell transplantation
Vesterbacka M; Ringden O; Remberger M; Huggare J; Dahllof G
Article: CLINICAL AND EXPERIMENTAL IMMUNOLOGY. 2012;167(3):543-555
Stromal cells from term fetal membrane are highly suppressive in allogeneic settings in vitro
Karlsson H; Erkers T; Nava S; Ruhm S; Westgren M; Ringden O
Article: TRANSPLANTATION AND CELLULAR THERAPY. 2011;17(12):1796-1803
Comparison of Reduced-Intensity Hematopoietic Cell Transplantation with Chemotherapy in Patients Age 60-70 Years with Acute Myelogenous Leukemia in First Remission
Farag SS; Maharry K; Zhang M-J; Perez WS; George SL; Mrozek K; DiPersio J; Bunjes DW; Marcucci G; Baer MR; Cairo M; Copelan E; Cutler CS; Isola L; Lazarus HM; Litzow MR; Marks DI; Ringden O; Rizzieri DA; Soiffer R; Larson RA; Tallman MS; Bloomfield CD; Weisdorf DJ
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 2011;87(6):503-509
Sirolimus and tacrolimus as immune prophylaxis compared to cyclosporine with or without methotrexate in patients undergoing allogeneic haematopoietic stem cell transplantation for non-malignant disorders
Ringden O; Remberger M; Dahllof G; Garming-Legert K; Karlsson H; Svenberg P; Uhlin M; Uzunel M; Mattsson J
Article: TRANSPLANTATION AND CELLULAR THERAPY. 2011;17(11):1688-1697
Improved Survival after Allogeneic Hematopoietic Stem Cell Transplantation in Recent Years. A Single-Center Study
Remberger M; Ackefors M; Berglund S; Blennow O; Dahllof G; Dlugosz A; Garming-Legert K; Gertow J; Gustafsson B; Hassan M; Hassan Z; Hauzenberger D; Hagglund H; Karlsson H; Klingspor L; Kumlien G; Le Blanc K; Ljungman P; Machaczka M; Malmberg K-J; Marschall H-U; Mattsson J; Olsson R; Omazic B; Sairafi D; Schaffer M; Svahn B-M; Svenberg P; Swartling L; Szakos A; Uhlin M; Uzunel M; Watz E; Wernerson A; Wikman A; Wikstrom A-C; Winiarski J; Ringden O
Article: ORAL DISEASES. 2011;17(7):670-676
Long-term salivary function after conditioning with busulfan, fractionated or single-dose TBI
Garming-Legert K; Remberger M; Ringden O; Hassan M; Dahllof G
Article: ORAL ONCOLOGY. 2011;47(9):915-919
Xerostomia in children and adolescents after stem cell transplantation conditioned with total body irradiation or busulfan
Dahllof G; Wondimu B; Barr-Agholme M; Garming-Legert K; Remberger M; Ringden O
Article: TRANSPLANT IMMUNOLOGY. 2011;25(2-3):153-158
Immune modulation to prevent antibody-mediated rejection after allogeneic hematopoietic stem cell transplantation
Nordlander A; Uhlin M; Ringden O; Kumlien G; Hauzenberger D; Mattsson J
Article: TRANSPLANTATION AND CELLULAR THERAPY. 2011;17(6):885-892
HLA-C Antigen Mismatch Is Associated with Worse Outcome in Unrelated Donor Peripheral Blood Stem Cell Transplantation
Woolfrey A; Klein JP; Haagenson M; Spellman S; Petersdorf E; Oudshoorn M; Gajewski J; Hale GA; Horan J; Battiwalla M; Marino SR; Setterholm M; Ringden O; Hurley C; Flomenberg N; Anasetti C; Fernandez-Vina M; Lee SJ
Article: TRANSPLANTATION AND CELLULAR THERAPY. 2011;17(5):640-648
One-Antigen Mismatched Related versus HLA-Matched Unrelated Donor Hematopoietic Stem Cell Transplantation in Adults with Acute Leukemia: Center for International Blood and Marrow Transplant Research Results in the Era of Molecular HLA Typing
Valcarcel D; Sierra J; Wang T; Kan F; Gupta V; Hale GA; Marks DI; McCarthy PL; Oudshoorn M; Petersdorf EW; Ringden O; Setterholm M; Spellman SR; Waller EK; Gajewski JL; Marino SR; Senitzer D; Lee SJ
Article: EUROPEAN JOURNAL OF IMMUNOLOGY. 2011;41(4):1143-1153
N-acetyl-L-cysteine increases acute graft-versus-host disease and promotes T-cell-mediated immunity in vitro
Karlsson H; Nava S; Remberger M; Hassan Z; Hassan M; Ringden O
Article: BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY. 2011;24(1):65-72
Mesenchymal stem cells for treatment of acute and chronic graft-versus-host disease, tissue toxicity and hemorrhages
Ringden O; Le Blanc K
Article: PEDIATRIC BLOOD & CANCER. 2011;56(3):444-451
Hematopoietic Stem Cell Transplantation in Severe Congenital Neutropenia
Carlsson G; Winiarski J; Ljungman P; Ringden O; Mattsson J; Nordenskjold M; Touw I; Henter J-I; Palmblad J; Fadeel B; Hagglund H
Article: BONE MARROW TRANSPLANTATION. 2011;46(2):200-207
Co-infusion of ex vivo-expanded, parental MSCs prevents life-threatening acute GVHD, but does not reduce the risk of graft failure in pediatric patients undergoing allogeneic umbilical cord blood transplantation
Bernardo ME; Ball LM; Cometa AM; Roelofs H; Zecca M; Avanzini MA; Bertaina A; Vinti L; Lankester A; Maccario R; Ringden O; Le Blanc K; Egeler RM; Fibbe WE; Locatelli F
Article: PLOS ONE. 2011;6(7):e21703
Mesenchymal Stromal Cells Engage Complement and Complement Receptor Bearing Innate Effector Cells to Modulate Immune Responses
Moll G; Jitschin R; von Bahr L; Rasmusson-Duprez I; Sundberg B; Lonnies L; Elgue G; Nilsson-Ekdahl K; Mougiakakos D; Lambris JD; Ringden O; Le Blanc K; Nilsson B
Article: CLINICAL TRANSPLANTATION. 2011;25(1):E68-E76
Second allogeneic hematopoietic stem cell transplantation: a treatment for graft failure
Remberger M; Mattsson J; Olsson R; Ringden O
Article: BONE MARROW TRANSPLANTATION. 2011;46(1):34-43
Comparative analysis of BU and CY versus CY and TBI in full intensity unrelated marrow donor transplantation for AML, CML and myelodysplasia
Uberti JP; Agovi M-A; Tarima S; Haagenson M; Gandham S; Anasetti C; Baker KS; Bolwell BJ; Bornhauser M; Chan KW; Copelan E; Davies SM; Finke J; Hale GA; Kollman C; McCarthy PL; Ratanatharathorn V; Ringden O; Weisdorf DJ; Rizzo JD
Article: HAEMATOLOGICA. 2010;95(12):2119-2125
Impact of age on outcomes after bone marrow transplantation for acquired aplastic anemia using HLA-matched sibling donors
Gupta V; Eapen M; Brazauskas R; Carreras J; Aljurf M; Gale RP; Hale GA; Ilhan O; Passweg JR; Ringden O; Sabloff M; Schrezenmeier H; Socie G; Marsh JCW
Article: BONE MARROW TRANSPLANTATION. 2010;45(12):1710-1718
Randomized PCR-based therapy and risk factors for invasive fungal infection following reduced-intensity conditioning and hematopoietic SCT
Blennow O; Remberger M; Klingspor L; Omazic B; Fransson K; Ljungman P; Mattsson J; Ringden O
Article: TRANSPLANTATION AND CELLULAR THERAPY. 2010;16(12):1728-1737
Leukemia Lineage-Specific Chimerism Analysis and Molecular Monitoring Improve Outcome of Donor Lymphocyte Infusions
Sairafi D; Remberger M; Uhlin M; Ljungman P; Ringden O; Mattsson J
Article: TRANSPLANTATION. 2010;90(9):1022-1029
Granulocyte Colony-Stimulating Factor Induced Acute and Chronic Graft-Versus-Host Disease
Ringden O; Hassan Z; Karlsson H; Olsson R; Omazic B; Mattsson J; Remberger M
Article: BLOOD. 2010;116(19):4007-4015
Outcomes of pediatric bone marrow transplantation for leukemia and myelodysplasia using matched sibling, mismatched related, or matched unrelated donors
Shaw PJ; Kan F; Ahn KW; Spellman SR; Aljurf M; Ayas M; Burke M; Cairo MS; Chen AR; Davies SM; Frangoul H; Gajewski J; Gale RP; Godder K; Hale GA; Heemskerk MBA; Horan J; Kamani N; Kasow KA; Chan KW; Lee SJ; Leung WH; Lewis VA; Miklos D; Oudshoorn M; Petersdorf EW; Ringden O; Sanders J; Schultz KR; Seber A; Setterholm M; Wall DA; Yu L; Pulsipher MA
Article: TRANSPLANTATION. 2010;90(2):124-126
Advancement of Mesenchymal Stem Cell Therapy in Solid Organ Transplantation (MISOT)
Hoogduijn MJ; Popp FC; Grohnert A; Crop MJ; van Rhijn M; Rowshani AT; Eggenhofer E; Renner P; Reinders ME; Rabelink TJ; van der Laan LJW; Dor FJMF; IJzermans JNM; Genever PG; Lange C; Durrbach A; Houtgraaf JH; Christ B; Seifert M; Shagidulin M; Donckier V; Deans R; Ringden O; Perico N; Remuzzi G; Bartholomew A; Schlitt HJ; Weimar W; Baan CC; Dahlke MH
Article: BLOOD. 2010;115(13):2686-2694
NK cells expressing inhibitory KIR for non-self-ligands remain tolerant in HLA-matched sibling stem cell transplantation
Bjorklund AT; Schaffer M; Fauriat C; Ringden O; Remberger M; Hammarstedt C; Barrett AJ; Ljungman P; Ljunggren H-G; Malmberg K-J
Article: BONE MARROW TRANSPLANTATION. 2010;45(4):682-688
Sequential Organ Failure Assessment predicts the outcome of SCT recipients admitted to intensive care unit
Gilli K; Remberger M; Hjelmqvist H; Ringden O; Mattsson J
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 2010;84(4):323-331
GVHD prophylaxis using low-dose cyclosporine improves survival in leukaemic recipients of HLA-identical sibling transplants
Olsson R; Remberger M; Hassan Z; Omazic B; Mattsson J; Ringden O
Article: BONE MARROW TRANSPLANTATION. 2010;45(2):235-238
Cytotoxic crossmatch analysis before allo-SCT is a poor diagnostic tool for prediction of rejection
Mattsson J; Nordlander A; Remberger M; Uhlin M; Holgersson J; Ringden O; Hauzenberger D
Article: JOURNAL OF IMMUNOTHERAPY. 2010;33(1):96-105
Clinical Expansion of Cord Blood-derived T Cells for Use as Donor Lymphocyte Infusion After Cord Blood Transplantation
Okas M; Gertow J; Uzunel M; Karlsson H; Westgren M; Karre K; Ringden O; Mattsson J; Uhlin M
Article: BONE MARROW TRANSPLANTATION. 2009;44(11):757-763
Allogeneic hematopoietic SCT in patients with non-malignant diseases, and importance of chimerism
Svenberg P; Mattsson J; Ringden O; Uzunel M
Article: TRANSPLANTATION AND CELLULAR THERAPY. 2009;15(10):1277-1287
The Effect of Smoking on Allogeneic Transplant Outcomes
Marks DI; Ballen K; Logan BR; Wang Z; Sobocinski KA; Bacigalupo A; Burns LJ; Gupta V; Ho V; McCarthy PL; Ringden O; Schouten HC; Seftel M; Rizzo JD
Article: VOX SANGUINIS. 2009;97(3):254-259
A randomized study of buffy coat platelets in platelet additive solution stored 1-5 versus 6-7 days prior to prophylactic transfusion of allogeneic haematopoietic progenitor cell transplant recipients
Diedrich B; Ringden O; Watz E; Shanwell A
Article: TRANSPLANT INFECTIOUS DISEASE. 2009;11(5):393-399
Targeted monitoring of patients at high risk of post-transplant lymphoproliferative disease by quantitative Epstein-Barr virus polymerase chain reaction
Omar H; Hagglund H; Gustafsson-Jernberg A; LeBlanc K; Mattsson J; Remberger M; Ringden O; Sparrelid E; Sundin M; Winiarski J; Yun Z; Ljungman P
Article: JOURNAL OF CLINICAL ONCOLOGY. 2009;27(27):4570-4577
Reduced Intensity Conditioning Compared With Myeloablative Conditioning Using Unrelated Donor Transplants in Patients With Acute Myeloid Leukemia
Ringden O; Labopin M; Ehninger G; Niederwieser D; Olsson R; Basara N; Finke J; Schwerdtfeger R; Eder M; Bunjes D; Gorin N-C; Mohty M; Rocha V
Article: TRANSPLANTATION AND CELLULAR THERAPY. 2009;15(9):1108-1115
Lymphocyte Recovery Is a Major Determinant of Outcome after Matched Unrelated Myeloablative Transplantation for Myelogenous Malignancies
Le Blanc K; Barrett AJ; Schaffer M; Hagglund H; Ljungman P; Ringden O; Remberger M
Article: JOURNAL OF IMMUNOTHERAPY. 2009;32(7):755-764
HSCT Recipients Have Specific Tolerance to MSC but not to the MSC Donor
Sundin M; Barrett AJ; Ringden O; Uzunel M; Lonnies H; Dackland A-L; Christensson B; Le Blanc K
Article: IMMUNOTHERAPY. 2009;1(5):753-764
Safety analysis of ex vivo-expanded NK and NK-like T cells administered to cancer patients: a Phase I clinical study
Barkholt L; Alici E; Conrad R; Sutlu T; Gilljam M; Stellan B; Christensson B; Guven H; Bjorkstrom NK; Soderdahl G; Cederlund K; Kimby E; Aschan J; Ringden O; Ljunggren H-G; Dilber MS
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2009;145(6):816-824
Prior rituximab correlates with less acute graft-versus-host disease and better survival in B-cell lymphoma patients who received allogeneic peripheral blood stem cell transplantation
Ratanatharathorn V; Logan B; Wang D; Horowitz M; Uberti JP; Ringden O; Gale RP; Khoury H; Arora M; Spellman S; Cutler C; Antin J; Bornhaeuser M; Hale G; Verdonck L; Cairo M; Gupta V; Pavletic S
Article: BONE MARROW TRANSPLANTATION. 2009;43(7):553-561
A prospective randomized controlled trial comparing PCR-based and empirical treatment with liposomal amphotericin Bin patients after allo-SCT
Hebart H; Klingspor L; Klingebiel T; Loeffler J; Tollemar J; Ljungman P; Wandt H; Schaefer-Eckart K; Dornbusch HJ; Meisner C; Engel C; Stenger N; Mayer T; Ringden O; Einsele H
Article: BLOOD. 2009;113(13):3110-3118
The graft-versus-leukemia effect using matched unrelated donors is not superior to HLA-identical siblings for hematopoietic stem cell transplantation
Ringden O; Pavletic SZ; Anasetti C; Barrett AJ; Wang T; Wang D; Antin JH; Di Bartolomeo P; Bolwell BJ; Bredeson C; Cairo MS; Gale RP; Gupta V; Hahn T; Hale GA; Halter J; Jagasia M; Litzow MR; Locatelli F; Marks DI; McCarthy PL; Cowan MJ; Petersdorf EW; Russell JA; Schiller GJ; Schouten H; Spellman S; Verdonck LF; Wingard JR; Horowitz MM; Arora M
Article: TRANSPLANTATION AND CELLULAR THERAPY. 2009;15(3):360-366
Recent Decrease in Acute Graft-versus-Host Disease in Children with Leukemia Receiving Unrelated Donor Bone Marrow Transplants
Davies SM; Wang D; Wang T; Arora M; Ringden O; Anasetti C; Pavletic S; Casper J; MacMillan ML; Sanders J; Wall D; Kernan NA
Article: TRANSPLANTATION AND CELLULAR THERAPY. 2009;15(3):326-335
Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation in Metastatic Colorectal Cancer as a Novel Adoptive Cell Therapy Approach. The European Group for Blood and Marrow Transplantation Experience
Aglietta M; Barkholt L; Schianca FC; Caravelli D; Omazic B; Minotto C; Leone F; Hentschke P; Bertoldero G; Capaldi A; Ciccone G; Niederwieser D; Ringden O; Demirer T
Article: TRANSPLANTATION. 2009;87(4):467-472
Increased Frequency and Responsiveness of PSA-Specific T Cells After Allogeneic Hematopoetic Stem-Cell Transplantation
Uhlin M; Okas M; Karlsson H; Gertow J; Henningsohn L; Ringden O; Karre K; Levitsky V; Mattsson J
Article: CYTOTHERAPY. 2009;11(2):129-136
Optimizing in vitro conditions for immunomodulation and expansion of mesenchymal stromal cells
Samuelsson H; Ringden O; Lonnies H; Le Blanc K
Article: JOURNAL OF CLINICAL ONCOLOGY. 2008;26(35):5728-5734
Risk Factors for Acute Graft-Versus-Host Disease After Human Leukocyte Antigen-Identical Sibling Transplants for Adults With Leukemia
Hahn T; McCarthy PLJ; Zhang M-J; Wang D; Arora M; Frangoul H; Gale RP; Hale GA; Horan J; Isola L; Maziarz RT; van Rood JJ; Gupta V; Halter J; Reddy V; Tiberghien P; Litzow M; Anasetti C; Pavletic S; Ringden O
Article: HLA. 2008;72(6):549-558
Outcome of haematopoietic stem cell transplantation in patients transplanted with matched unrelated donors vs allele-mismatched donors: a single centre study
Hauzenberger D; Schaffer M; Ringden O; Hassan Z; Omazic B; Mattsson J; Wikstrom A-C; Remberger M
Article: BONE MARROW TRANSPLANTATION. 2008;42(10):643-648
Unrelated cord blood and mismatched unrelated volunteer donor transplants, two alternatives in patients who lack an HLA-identical donor
Ringden O; Okas M; Uhlin M; Uzunel M; Remberger M; Mattsson J
Article: BONE MARROW TRANSPLANTATION. 2008;42(3):201-205
Donor leukocyte infusions to treat hematologic malignancy relapse following allo-SCT in a pediatric population
Levine JE; Barrett AJ; Zhang M-J; Arora M; Pulsipher MA; Bunin N; Fort J; Loberiza F; Porter D; Giralt S; Drobyski W; Wang D; Pavletic S; Ringden O; Horowitz MM; Collins RJ
Article: BONE MARROW TRANSPLANTATION. 2008;42(3):175-180
Unrelated donor hematopoietic cell transplantation for hemophagocytic lymphohistiocytosis
Baker KS; Filipovich AH; Gross TG; Grossman WJ; Hale GA; Hayashi RJ; Kamani NR; Kurian S; Kapoor N; Ringden O; Eapen M
Article: ACTA PAEDIATRICA. 2008;97(8):1108-1112
Outcome in six children with mucopolysaccharidosis type IH, hurler syndrome, after haematopoietic stem cell transplantation (HSCT)
Malm G; Gustafsson B; Berglund G; Lindstrom M; Naess K; Borgstrom B; von Dobeln U; Ringden O
Article: BLOOD. 2008;112(3):532-541
Mesenchymal stem cells exert differential effects on alloantigen and virus-specific T-cell responses
Karlsson H; Samarasinghe S; Ball LM; Sundberg B; Lankester AC; Dazzi F; Uzunel M; Rao K; Veys P; Le Blanc K; Ringden O; Amrolia PJ
Article: BONE MARROW TRANSPLANTATION. 2008;41(11):961-964
No impact of NOD2/CARD15 on outcome after SCT
Sairafi D; Uzunel M; Remberger M; Ringden O; Mattsson J
Article: LANCET. 2008;371(9624):1579-1586
Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease:: a phase II study
LeBlanc K; Frassoni F; Ball L; Locatelli F; Roelofs H; Lewis I; Lanino E; Sundberg B; Bernardo ME; Remberger M; Dini G; Egeler RM; Bacigalupo A; Fibbe W; Ringden O
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 2008;80(5):419-428
Genomic tissue typing and optimal antithymocyte globuline dose using unrelated donors results in similar survival and relapse as HLA-identical siblings in haematopoietic stem-cell transplantation for leukaemia
Remberger M; Mattsson J; Hausenberger D; Schaffer M; Svahn B-M; Ringden O
Article: BONE MARROW TRANSPLANTATION. 2008;41(9):785-790
A prospective randomized study using N-acetyl-L-cysteine for early liver toxicity after allogeneic hematopoietic stem cell transplantation
Barkholt L; Remberger M; Hassan Z; Fransson K; Omazic B; Svahn B-M; Karlsson H; Brune M; Hassan M; Mattsson J; Ringden O
Article: APMIS. 2008;116(5):345-351
A prospective study of diagnosis of Toxoplasma gondii infection after bone marrow transplantation
Edvinsson B; Lundquist J; Ljungman P; Ringden O; Evengard B
Article: TRANSPLANTATION. 2008;85(7):1000-1007
Case-control comparison of at-home and hospital care for allogeneic hematopoietic stem-cell transplantation:: The role of oral nutrition
Svahn B-M; Remberger M; Heijbel M; Martell E; Wikstrom M; Eriksson B; Milovsavljevic R; Mattsson J; Ringden O
Article: BONE MARROW TRANSPLANTATION. 2008;41(8):737-742
BK-viruria and haemorrhagic cystitis are more frequent in allogeneic haematopoietic stem cell transplant patients receiving full conditioning and unrelated-HLA-mismatched grafts
Giraud G; Priftakis P; Bogdanovic G; Remberger M; Dubrulle M; Hau A; Gutmark R; Mattson J; Svahn B-M; Ringden O; Winiarski J; Ljungman P; Dalianis T
Article: BONE MARROW TRANSPLANTATION. 2008;41(7):621-625
Safe administration of oral BU twice daily during conditioning for stem cell transplantation in a paediatric population:: A comparative study between the standard 4-dose and a 2-dose regimen
Mellgren K; Nilsson C; Fasth A; Abrahamsson J; Winiarski J; Ringden O; Hassan M
Article: HAEMATOLOGICA. 2008;93(2):265-272
A comparison between low intensity and reduced intensity conditioning in allogeneic hematopoietic stem cell transplantation for solid tumors
Conrad R; Remberger M; Cederlund K; Ringden O; Barkholt L
Article: BONE MARROW TRANSPLANTATION. 2008;41(3):267-273
Allogeneic stem cell transplantation:: low immunoglobulin levels associated with decreased survival
Norlin A-C; Sairafi D; Mattsson J; Ljungman P; Ringden O; Remberger M
Article: BONE MARROW TRANSPLANTATION. 2008;41(4):399-405
Risk factors for acute graft-versus-host disease grades II-IV after reduced intensity conditioning allogeneic stem cell transplantation with unrelated donors -: a single centre study
Remberger M; Mattsson J; Hassan Z; Karlsson N; LeBlanc K; Omazic B; Okas M; Sairafi D; Ringden O
Article: TRANSPLANTATION AND CELLULAR THERAPY. 2008;14(1):165-170
Graft failure after allogeneic hematopoietic cell transplantation
Mattsson J; Ringden O; Storb R
Article: CYTOTHERAPY. 2008;10(3):238-242
No increased trapping of multipotent mesenchymal stromal cells in bone marrow filters compared with other bone marrow cells
Sundin M; Remberger M; Lonnies H; Sundberg B; Ringden O; Le Blanc K
Article: BLOOD. 2007;110(13):4560-4566
The importance of HLA-DPB1 in unrelated donor hematopoietic cell transplantation
Shaw BE; Gooley TA; Malkki M; Madrigal JA; Begovich AB; Horowitz MM; Gratwohl A; Ringden O; Marsh SGE; Petersdorf EW
Article: BONE MARROW TRANSPLANTATION. 2007;40(11):1055-1062
Risk factors for fatal infectious complications developing late after allogeneic stem cell transplantation
Bjorklund A; Aschan J; Labopin M; Remberger M; Ringden O; Winiarski J; Ljungman P
Article: BONE MARROW TRANSPLANTATION. 2007;40(9):865-869
Evaluation of intervention strategy based on CMV-specific immune responses after allogeneic SCT
Avetisyan G; Aschan J; Haegglund H; Ringden O; Ljungman P
Article: JOURNAL OF CLINICAL IMMUNOLOGY. 2007;27(6):589-597
Enhanced In vivo protein synthesis in circulating immune cells of ICU patients
Januszkiewicz A; Klaude M; Lore K; Andersson J; Ringden O; Rooyackers O; Wernerman J
Article: LEUKEMIA. 2007;21(11):2271-2276
Tissue repair using allogeneic mesenchymal stem cells for hemorrhagic cystitis, pneumomediastinum and perforated colon
Ringden O; Uzunel M; Sundberg B; Lonnies L; Nava S; Gustafsson J; Henningsohn L; Le Blanc K
Article: TRANSPLANTATION. 2007;84(8):1055-1059
Generation of immunosuppressive mesenchymal stem cells in allogeneic human serum
Le Blanc K; Samuelsson H; Lönnies L; Sundin M; Ringdén O
Article: BONE MARROW TRANSPLANTATION. 2007;40(7):683-689
Cyclosporine A (CsA) 2-h concentrations vary between patients without correlation to graft-versus-host disease after allogeneic haematopoietic stem cell transplantation
Barkholt L; Remberger M; Bodegard H; Ringden O; Botttiger Y
Article: CLINICAL TRANSPLANTATION. 2007;21(5):659-667
Hemorrhagic cystitis:: a retrospective single-center survey
Hassan Z; Remberger M; Svenberg P; Elbander M; Omazic B; Mattsson J; Conrad R; Svahn B-M; Ahlgren A; Sairafi D; Aschan J; Le Blanc K; Barkholt L; Ringden O
Article: HAEMATOLOGICA. 2007;92(9):1208-1215
No alloantibodies against mesenchymal stromal cells, but presence of anti-fetal calf serum antibodies, after transplantation in allogeneic hematopoietic stem cell recipients
Sundin M; Ringden O; Sundberg B; Nava S; Gotherstrom C; Le Blanc K
Article: TRANSPLANTATION. 2007;84(4):551-554
Similar outcome after unrelated allogeneic peripheral blood stem cell transplantation compared with bone marrow in children and adolescents
Remberger M; Ringden O
Article: LEUKEMIA. 2007;21(8):1733-1738
Transplantation of mesenchymal stem cells to enhance engraftment of hematopoietic stem cells
Le Blanc K; Samuelsson H; Gustafsson B; Remberger M; Sundberg B; Arvidson J; Ljungman P; Lonnies H; Nava S; Ringden O
Article: TRANSPLANTATION AND CELLULAR THERAPY. 2007;13(6):675-682
Major ABO blood group mismatch increases the risk for graft failure after unrelated donor hematopoietic stem cell transplantation
Remberger M; Watz E; Ringdén O; Mattsson J; Shanwell A; Wikman A
Article: SCANDINAVIAN JOURNAL OF IMMUNOLOGY. 2007;65(4):336-343
Mesenchymal stem cells stimulate antibody secretion in human B cells
Rasmusson I; Le Blanc K; Sundberg B; Ringden O
Article: BONE MARROW TRANSPLANTATION. 2007;39(7):383-388
Fludarabine-based disease-specific conditioning or conventional myeloablative conditioning in hematopoietic stem cell transplantation for treatment of non-malignant diseases
Ringden O; Remberger M; Svenberg P; Svahn B-M; Dahllof G; Gustafsson B; Hassan Z; Omazic B; Uzunel M; Aschan J; Barkholt L; Winiarski J; Ljungman P; Mattsson J
Article: INTERNATIONAL JOURNAL OF PAEDIATRIC DENTISTRY. 2007;17(1):34-40
Longitudinal scintigraphic study of parotid and submandibular gland function after total body irradiation in children and adolescents
Bagesund M; Richter S; Ringden O; Dahllof G
Article: TRANSPLANTATION. 2006;82(7):913-919
Unrelated versus related allogeneic stem cell transplantation after reduced intensity conditioning
Uzunel M; Remberger M; Sairafi D; Hassan Z; Mattsson J; Omazic B; Barkholt L; Ringden O
Article: TRANSPLANTATION AND CELLULAR THERAPY. 2006;12(8):828-836
KIR Ligands and prediction of relapse after unrelated donor hematopoietic cell transplantation for hematologic malignancy
Hsu KC; Gooley T; Malkki M; Pinto-Agnello C; Dupont B; Bignon J-D; Bornhaeuser M; Christiansen F; Gratwohl A; Morishnna Y; Oudshoorn M; Ringden O; van Rood JJ; Petersdorf E
Article: HAEMATOLOGICA. 2006;91(8):1059-1067
The role of HLA mismatch, splenectomy and recipient Epstein-Barr virus seronegativity as risk factors in post-transplant lymphoproliferative disorder following allogeneic hematopoietic stem cell transplantation
Sundin M; Le Blanc K; Ringden O; Barkholt L; Omazic B; Lergin C; Levitsky V; Remberger M
Article: TRANSPLANTATION. 2006;82(2):147-153
Costs of allogeneic hematopoietic stem cell transplantation
Svahn B-M; Alvin O; Ringden O; Gardulf A; Remberger M
Article: ANNALS OF ONCOLOGY. 2006;17(7):1134-1140
Allogeneic haematopoietic stem cell transplantation for metastatic renal carcinoma in Europe
Barkholt L; Bregni M; Remberger M; Blaise D; Peccatori J; Massenkeil G; Pedrazzoli P; Zambelli A; Bay J-O; Francois S; Martino R; Bengala C; Brune M; Lenhoff S; Porcellini A; Falda M; Siena S; Demirer T; Niederwieser D; Ringden O
Article: TRANSPLANTATION. 2006;81(11):1600-1603
Treatment costs and survival in patients with grades III-IV acute graft-versus-host disease after allogenic hematopoietic stem cell transplantation during three decades
Svahn B-M; Ringden O; Remberger M
Article: BONE MARROW TRANSPLANTATION. 2006;37(11):1051-1059
Mesenchymal stem cells are susceptible to human herpesviruses, but viral DNA cannot be detected in the healthy seropositive individual
Sundin M; Orvell C; Rasmusson I; Sundberg B; Ringden O; Le Blanc K
Article: TRANSPLANTATION. 2006;81(10):1390-1397
Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease
Ringden O; Uzunel M; Rasmusson I; Remberger M; Sundberg B; Lonnies H; Marschall H-U; Dlugosz A; Szakos A; Hassan Z; Omazic B; Aschan J; Barkholt L; Le Blanc K
Article: TRANSPLANTATION. 2006;81(5):718-725
Allogeneic hematopoietic stem cell transplantation for inherited disorders:: Experience in a single center
Ringdén O; Remberger M; Svahn BM; Barkholt L; Mattsson J; Aschan J; Le Blanc K; Gustafsson B; Hassan Z; Omazic B; Svenberg P; Solders G; von Döbeln U; Winiarski J; Ljungman P; Malm G
Article: HAEMATOLOGICA. 2006;91(3):401-404
The incidence of hemorrhagic cystitis and BK-viruria in allogeneic hematopoietic stem cell recipients according to intensity of the conditioning regimen
Giraud G; Bogdanovic G; Priftakis P; Remberger M; Svahn B-M; Barkholt L; Ringden O; Winiarski J; Ljungman P; Dalianis T
Article: TRANSPLANTATION AND CELLULAR THERAPY. 2006;12(3):346-354
Inflammatory cytokines predominate in cases of tumor regression after hematopoietic stem cell transplantation for solid cancer
Conrad R; Remberger M; Cederlund K; Hentschke P; Sundberg B; Ringdén O; Barkholt L
Article: BLOOD. 2006;107(4):1712-1716
Impact of posttransplantation G-CSF on outcomes of allogeneic hematopoietic stem cell transplantation
Khoury HJ; Loberiza FR; Ringdén O; Barrett AJ; Bolwell BJ; Cahn JY; Champlin RE; Gale RP; Hale GA; Urbano-Ispizua A; Martino R; McCarthy PL; Tiberghien P; Verdonck LF; Horowitz MM
Article: HAEMATOLOGICA. 2006;91(1):78-83
Risk factors for the development of cytomegalovirus disease after allogeneic stem cell transplantation
Ljungman P; Perez-Bercoff L; Jonsson J; Avetisyan G; Sparrelid E; Aschan J; Barkholt L; Larsson K; Winiarski J; Yun Z; Ringden O
Article: SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES. 2006;38(11-12):970-976
Decreasing mortality rate in early pneumonia following hematopoietic stem cell transplantation
Forslow U; Mattsson J; Ringden O; Klominek J; Remberger M
Article: TRANSPLANTATION AND CELLULAR THERAPY. 2005;11(12):1006-1013
ABO blood group barrier in allogeneic bone marrow transplantation revisited
Seebach JD; Stussi G; Passweg JR; Loberiza FR; Gajewski JL; Keating A; Goerner M; Rowlings PA; Tiberghien P; Elfenbein GJ; Gale RP; van Rood JJ; Reddy V; Gluckman E; Bolwell BJ; Klumpp TR; Horowitz MM; Ringdén O; Barrett AJ
Article: CANCER. 2005;104(10):2099-2103
Prognostic factors for survival in patients with advanced renal cell carcinoma undergoing nonmyeloablative allogeneic stem cell transplantation
Peccatori J; Barkholt L; Demirer T; Sormani MP; Bruzzi P; Ciceri F; Zambelli A; Da Prada GA; Pedrazzoli P; Siena S; Massenkeil G; Martino R; Lenhoff S; Corradini P; Rosti G; Ringden O; Bregni M; Niederwieser D
Article: BLOOD. 2005;106(9):2969-2976
Outcomes of reduced-intensity transplantation for chronic myeloid leukemia: an analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT
Crawley C; Szydlo R; Lalancette M; Bacigalupo A; Lange A; Brune M; Juliusson G; Nagler A; Gratwohl A; Passweg J; Komarnicki M; Vitek A; Mayer J; Zander A; Sierra J; Rambaldi A; Ringden O; Niederwieser D; Apperley JF
Article: BONE MARROW TRANSPLANTATION. 2005;36(6):511-516
Long-term follow-up of patients treated at home during the pancytopenic phase after allogeneic haematopoietic stem cell transplantation
Svahn BM; Ringdén O; Remberger M
Article: BLOOD. 2005;106(4):1495-1500
Prospective evaluation of 2 acute graft-versus-host (GVHD) grading systems:: a joint Societe Francaise de Greffe de Moelle et Therapie Cellulaire (SFGM-TC), Dana Farber Cancer Institute (DFCI), and International Bone Marrow Transplant Registry (IBMTR) prospective study
Cahn JY; Klein JP; Lee SJ; Milpied N; Blaise D; Antin JH; Leblond V; Ifrah N; Jouet JP; Loberiza F; Ringden O; Barrett AJ; Horowitz MM; Socié G
Article: TRANSFUSION. 2005;45(7):1064-1072
A prospective randomized trial of a prophylactic platelet transfusion trigger of 10 x 10⁹ per L versus 30 x 10⁹ per L in allogeneic hematopoietic progenitor cell transplant recipients
Diedrich B; Remberger M; Shanwell A; Svahn BM; Ringdén O
Article: TRANSPLANTATION. 2005;79(11):1607-1614
Fetal mesenchymal stem-cell engraftment in bone after in utero transplantation in a patient with severe osteogenesis imperfecta
Le Blanc K; Götherström C; Ringdén O; Hassan M; McMahon R; Horwitz E; Anneren G; Axelsson O; Nunn J; Ewald U; Nordén-Lindeberg S; Jansson M; Dalton A; Åström E; Westgren M
Article: EXPERIMENTAL CELL RESEARCH. 2005;305(1):33-41
Mesenchymal stem cells inhibit lymphocyte proliferation by mitogens and alloantigens by different mechanisms
Rasmusson I; Ringdén O; Sundberg B; Le Blanc K
Article: SCANDINAVIAN JOURNAL OF IMMUNOLOGY. 2005;61(3):285-294
T-cell receptor Vβ repertoire after myeloablative and reduced intensity conditioning allogeneic haematopoietic stem cell transplantation
Hentschke P; Omazic B; Mattsson J; Näsman-Björk I; Lundkvist I; Gigliotti D; Barkholt L; Ringdén O; Remberger M
Article: BLOOD. 2005;105(4):1408-1416
Comparison of graft-versus-host-disease and survival after HLA-identical sibling bone marrow transplantation in ethnic populations
Oh H; Loberiza FR; Zhang MJ; Ringdén O; Akiyama H; Asai T; Miyawaki S; Okamoto S; Horowitz MM; Antin JH; Bashey A; Bird JM; Carabasi MH; Fay JW; Gale RP; Giller RH; Goldman JM; Hale GA; Harris RE; Henslee-Downey J; Kolb HJ; Litzow MR; McCarthy PL; Neudorf SM; Serna DS; Socié G; Tiberghien P; Barrett AJ
Article: CLINICAL SCIENCE. 2005;108(2):179-184
Determination of in vivo protein synthesis in human palatine tonsil
Januszkiewicz A; Klaude M; Loré K; Andersson J; Ringdén O; Rooyackers O; Wernerman J
Article: BLOOD. 2005;105(2):548-551
Increased risk of extensive chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplantation using unrelated donors
Remberger M; Beelen DW; Fauser A; Basara N; Basu O; Ringdén O
Article: SCANDINAVIAN JOURNAL OF IMMUNOLOGY. 2005;61(1):72-81
Reconstitution of the ig heavy chain CDR3 repertoire after allogeneic haematopoietic stem cell transplantation with myeloablative or reduced-intensity conditioning regimens
Omazic B; Hentschke P; Näsman-Björk I; Mattsson J; Oxelius VA; Ringdén O; Barkholt L; Permert J; Lundkvist I
Article: TRANSPLANTATION AND CELLULAR THERAPY. 2004;10(12):877-882
Allogenic stem cell transplantation for nonmalignant disorders using matched unrelated donors
Svenberg P; Remberger M; Svennilson J; Mattsson J; Leblanc K; Gustafsson B; Aschan J; Barkholt L; Winiarski J; Ljungman P; Ringdén O
Article: BONE MARROW TRANSPLANTATION. 2004;34(12):1067-1069
Long-term immunity to poliovirus after vaccination of allogeneic stem cell transplant recipients
Ljungman P; Aschan J; Gustafsson B; Lewensohn-Fuchs I; Winiarski J; Ringdén O
Article: TRANSPLANTATION. 2004;78(7):1081-1085
Increased infection-related mortality in KIR-ligand-mismatched unrelated allogeneic hematopoietic stem-cell transplantation
Schaffer M; Malmberg KJ; Ringdén O; Ljunggren HG; Remberger M
Article: TRANSPLANTATION. 2004;78(7):1014-1020
A comparison of nonmyeloablative and reduced-intensity conditioning for allogeneic stem-cell transplantation
Le Blanc K; Remberger M; Uzunel M; Mansson J; Barkholt L; Ringdén O
Article: PEDIATRIC TRANSPLANTATION. 2004;8(5):464-474
Risk factors in pediatric stem cell transplantation for leukemia
Jernberg Å; Remberger M; Ringdén O; Winiarski J
Article: CLINICAL TRANSPLANTATION. 2004;18(5):518-524
Effect of combined T- and B-cell depletion of allogeneic HLA-mismatched bone marrow graft on the magnitude and kinetics of Epstein-Barr virus load in the peripheral blood of bone marrow transplant recipients
Liu DR; Tammik C; Zou JZ; Ernberg I; Masucci MG; Ringden O; Levitsky V
Article: BONE MARROW TRANSPLANTATION. 2004;34(8):721-727
Second transplant for acute and chronic leukemia relapsing after first HLA-identical sibling transplant
Eapen M; Giralt SA; Horowitz MM; Klein JP; Wagner JE; Zhang MJ; Tallman MS; Marks DI; Camitta BM; Champlin RE; Ringdén O; Bredeson CN; Martino R; Gale RP; Cairo MS; Litzow MR; deLima M
Article: BONE MARROW TRANSPLANTATION. 2004;34(7):589-593
Measles immunity after allogeneic stem cell transplantation;: influence of donor type, graft type, intensity of conditioning, and graft-versus host disease
Ljungman P; Aschan J; Barkholt L; Broliden PA; Gustafsson B; Lewensohn-Fuchs I; Löfgren C; Winiarski J; Ringdén O
Article: TRANSPLANTATION. 2004;78(5):697-703
Indium-111-labelled donor-lymphocyte infusion by way of hepatic artery and radio-frequency ablation against liver metastases of renal and colon carcinoma after allogeneic hematopoietic stem-cell transplantation
Barkholt L; Danielsson R; Calissendorff B; Svensson L; Malihi R; Remberger M; Uzunel M; Thörne A; Ringdén O
Article: SCANDINAVIAN JOURNAL OF IMMUNOLOGY. 2004;60(3):307-315
Mesenchymal stem cells inhibit the expression of CD25 (interleukin-2 receptor) and CD38 on phytohaemagglutinin-activated lymphocytes
Le Blanc K; Rasmusson I; Götherström C; Seidel C; Sundberg B; Sundin M; Rosendahl K; Tammik C; Ringdén O
Article: TRANSPLANTATION. 2004;78(3):415-419
Five-year follow-up of two siblings with aspartylglucosaminuria undergoing allogeneic stem-cell transplantation from unrelated donors
Malm G; Månsson JE; Winiarski J; Mosskin M; Ringdén O
Article: TRANSPLANTATION. 2004;78(1):122-127
Dose study of thymoglobulin during conditioning for unrelated donor allogeneic stem-cell transplantation
Remberger M; Svahn BM; Mattsson J; Ringdén O
Article: JOURNAL OF CLINICAL ONCOLOGY. 2004;22(14):2816-2825
Outcome of allogeneic hematopoietic stem-cell transplantation in adult patients with acute lymphoblastic leukemia: No difference in related compared with unrelated transplant in first complete remission
Kiehl MG; Kraut L; Schwerdtfeger R; Hertenstein B; Remberger M; Kroeger N; Stelljes M; Bornhaeuser M; Martin H; Scheid C; Ganser A; Zander AR; Kienast J; Ehninger G; Hoelzer D; Diehl V; Fauser AA; Ringden O
Article: LANCET. 2004;363(9419):1439-1441
Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells
Le Blanc K; Rasmusson I; Sundberg B; Götherström C; Hassan M; Uzunel M; Ringdén O
Article: JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY. 2004;127(5):1293-1300
Xenoreactivity and engraftment of human mesenchymal stem cells transplanted into infarcted rat myocardium
Grinnemo KH; Månsson A; Dellgren G; Klingberg D; Wardell E; Drvota V; Tammik C; Holgersson J; Ringdén O; Sylvén C; Le Blanc K
Article: PRESSE MEDICALE. 2004;33(7):474-478
Is it safe to treat allogeneic stem cell transplanted recipients at home during the pancytopenic phase?
Svahn BM; Bjurman B; Myrbäck KE; Aschan J; Ringdén O
Article: TRANSPLANTATION AND CELLULAR THERAPY. 2004;10(3):195-203
Graft-versus-Host disease is associated with a lower relapse incidence after hematopoietic stem cell transplantation in patients with acute lymphoblastic leukemia
Nordlander A; Mattsson J; Ringdén O; Leblanc K; Gustafsson B; Ljungman P; Svenberg P; Svennilson J; Remberger M
Article: TRANSPLANTATION. 2004;77(4):526-531
Reduced risk for extensive chronic graft-versus-host disease in patients receiving transplants with human leukocyte antigen-identical sibling donors given polymerase chain reaction-based preemptive therapy against cytomegalovirus
Larsson K; Aschan J; Remberger M; Ringdén O; Winiarski J; Ljungman P
Article: TRANSPLANTATION AND CELLULAR THERAPY. 2004;10(2):128-134
Which donor should be chosen for hematopoietic stem cell transplantation among unrelated HLA-A, -B, and-DRB1 genomically identical volunteers?
Ringdén O; Schaffer M; Le Blanc AA; Persson U; Hauzenberger D; Abedi MR; Olerup O; Ljungman P; Remberger M
Article: JOURNAL OF CLINICAL ONCOLOGY. 2004;22(3):416-423
Treatment with granulocyte colony-stimulating factor after allogeneic bone marrow transplantation for acute leukemia increases the risk of graft-versus-host disease and death:: A study from the acute leukemia working party of the European Group for Blood and Marrow Transplantation
Ringdén O; Labopin M; Gorin NC; Le Blanc K; Rocha V; Gluckman E; Reiffers J; Arcese W; Vossen JM; Jouet JP; Cordonnier C; Frassoni F
Article: AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY. 2004;190(1):239-245
Immunologic properties of human fetal mesenchymal stem cells
Götherström C; Ringdén O; Tammik C; Zetterberg E; Westgren M; Le Blanc K
Article: BONE MARROW TRANSPLANTATION. 2004;33(1):79-85
Viridans streptococcal septicaemia in neutropenic patients:: role of proinflammatory cytokines
Ihendyane N; Sparrelid E; Wretlind B; Remberger M; Andersson J; Ljungman P; Ringdén O; Normark BH; Allen U; Low DE; Norrby-Teglund A
Article: BONE MARROW TRANSPLANTATION. 2004;33(1):47-52
Poor correlation of kinetics between BCR-ABL and WT1 transcript levels after allogeneic stem cell transplantation
Uzunel M; Ringdén O
Article: TRANSPLANTATION. 2003;76(8):1208-1213
Mesenchymal stem cells inhibit the formation of cytotoxic T lymphocytes, but not activated cytotoxic T lymphocytes or natural killer cells
Rasmusson I; Ringdén O; Sundberg B; Le Blanc K
Article: BLOOD. 2003;102(8):3043-3051
Marrow versus peripheral blood for geno-identical allogeneic stem cell transplantation in acute myelocytic leukemia: influence of dose and stem cell source shows better outcome with rich marrow
Gorin NC; Labopin M; Rocha V; Arcese W; Beksac M; Gluckman E; Ringden O; Ruutu T; Reiffers J; Bandini G; Falda M; Zikos P; Willemze R; Frassoni F
Article: EXPERIMENTAL HEMATOLOGY. 2003;31(10):890-896
HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells
Le Blanc K; Tammik C; Rosendahl K; Zetterberg E; Ringdén O
Article: HAEMATOLOGICA. 2003;88(9):1044-1052
A low body mass index is correlated with poor survival after allogeneic stem cell transplantation
Le Blanc K; Ringdén O; Remberger M
Article: HLA. 2003;62(3):243-250
Roles of HLA-B, HLA-C and HLA-DPA1 incompatibilities in the outcome of unrelated stem-cell transplantation
Schaffer M; Aldener-Cannavá A; Remberger M; Ringdén O; Olerup O
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2003;122(5):788-794
Minimal residual disease detection after allogeneic stem cell transplantation is correlated to relapse in patients with acute lymphoblastic leukaemia
Uzunel M; Jaksch M; Mattsson J; Ringdén O
Article: BONE MARROW TRANSPLANTATION. 2003;32(4):349-354
N-acetyl-L-cysteine does not affect the pharmacokinetics or myelosuppressive effect of busulfan during conditioning prior to allogeneic stem cell transplantation
Sjöö F; Aschan J; Barkholt L; Hassan Z; Ringdén O; Hassan M
Article: BONE MARROW TRANSPLANTATION. 2003;32(3):265-272
Immunomodulatory effects of human foetal liver-derived mesenchymal stem cells
Götherström C; Ringdén O; Westgren M; Tammik C; Le Blanc K
Article: TRANSPLANTATION. 2003;76(2):423-426
Increased levels of syndecan-1 in serum during acute graft-versus-host disease
Seidel C; Ringdén O; Remberger M
Article: TRANSPLANTATION. 2003;76(1):204-209
In vitro studies of the role of CD3⁺ and CD56⁺ cells in fetal liver cell alloreactivity
Lindton B; Markling L; Ringdén O; Westgren M
Article: BONE MARROW TRANSPLANTATION. 2003;32(2):217-223
G-CSF given after haematopoietic stem cell transplantation using HLA-identical sibling donors is associated to a higher incidence of acute GVHD II-IV
Remberger M; Naseh N; Aschan J; Barkholt L; LeBlanc K; Svennberg P; Ringdén O
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2003;121(6):874-885
Decreased treatment failure in recipients of HLA-identical bone marrow or peripheral blood stem cell transplants with high CD34 cell doses
Ringdén O; Barrett AJ; Zhang MJ; Loberiza FR; Bolwell BJ; Cairo MS; Gale RP; Hale GA; Litzow MR; Martino R; Russell JA; Tiberghien P; Urbano-Ispizua A; Horowitz MM
Article: TRANSPLANTATION. 2003;75(7):1061-1066
Liver transplantation followed by adjuvant nonmyeloablative hemopoietic stem cell transplantation for advanced primary liver cancer in humans
Söderdahl G; Barkholt L; Hentschke P; Mattsson J; Uzunel M; Ericzon BG; Ringdén O
Article: PEDIATRIC TRANSPLANTATION. 2003;7(2):130-136
Risk factors for moderate-to-severe acute graft-vs.-host disease after allogeneic stem cell transplantation in children
Svennilson J; Remberger M; Ringdén O
Article: BONE MARROW TRANSPLANTATION. 2003;31(6):429-435
The effect of metronidazole on busulfan pharmacokinetics in patients undergoing hematopoietic stem cell transplantation
Nilsson C; Aschan J; Hentschke P; Ringdén O; Ljungman P; Hassan M
Article: BONE MARROW TRANSPLANTATION. 2003;31(3):175-181
Graft-versus-leukaemia effect in children:: chronic GVHD has a significant impact on relapse and survival
Jernberg Å; Remberger M; Ringdén O; Winiarski J
Article: BONE MARROW TRANSPLANTATION. 2003;31(4):253-261
Reduced intensity conditioning regimens -: Low-intensity conditioning and hematopoietic stem cell transplantation in patients with renal and colon carcinoma
Hentschke P; Barkholt L; Uzunel M; Mattsson J; Wersäll P; Pisa P; Martola J; Albiin N; Wernerson A; Söderberg M; Remberger M; Thörne A; Ringdén O
Article: BLOOD. 2003;101(2):469-472
Kinetics of minimal residual disease and chimerism in patients with chronic myeloid leukemia after nonmyeloablative conditioning and allogeneic stem cell transplantation
Uzunel M; Mattsson J; Brune M; Johansson JE; Aschan J; Ringdén O
Article: BONE MARROW TRANSPLANTATION. 2003;31(1):23-29
Patients with acute lymphoblastic leukaemia allografted with a matched unrelated donor may have a lower survival with a peripheral blood stem cell graft compared to bone marrow
Garderet L; Labopin M; Gorin NC; Polge E; Fouillard L; Ehninger GE; Ringden O; Finke J; Tura S; Frassoni F
Article: SCANDINAVIAN JOURNAL OF IMMUNOLOGY. 2003;57(1):11-20
Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex
Le Blanc K; Tammik L; Sundberg B; Haynesworth SE; Ringdén O
Article: JOURNAL OF CLINICAL ONCOLOGY. 2002;20(24):4655-4664
Transplantation of peripheral blood stem cells as compared with bone marrow from HLA-identical siblings in adult patients with acute myeloid leukemia and acute lymphoblastic leukemia
Ringdén O; Labopin M; Bacigalupo A; Arcese W; Schaefer UW; Willemze R; Koc H; Bunjes D; Gluckman E; Rocha V; Schattenberg A; Frassoni F
Article: BLOOD. 2002;100(13):4317-4324
Home care during the pancytopenic phase after allogeneic hematopoietic stem cell transplantation is advantageous compared with hospital care
Svahn BM; Remberger M; Myrbäck KE; Holmberg K; Eriksson B; Hentschke P; Aschan J; Barkholt L; Ringdén O
Article: BONE MARROW TRANSPLANTATION. 2002;30(12):833-841
A phase II trial of liposomal busulphan as an intravenous myeloablative agent prior to stem cell transplantation:: 500 mg/m² as a optimal total dose for conditioning
Hassan M; Nilsson C; Hassan Z; Gungor T; Aschan J; Winiarski J; Hentschke P; Ringdén O; Eber S; Seger R; Ljungman P
Article: BONE MARROW TRANSPLANTATION. 2002;30(11):761-768
The graft-versus-leukaemia effect in haematopoietic stem cell transplantation using unrelated donors
Remberger M; Mattsson J; Hentschke P; Aschan J; Barkholt L; Svennilson J; Ljungman P; Ringdén O
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2002;119(3):751-759
An association between human leucocyte antigen alleles and acute and chronic graft-versus-host disease after allogeneic haematopoietic stem cell transplantation
Remberger M; Persson U; Hauzenberger D; Ringdén O
Article: CLINICAL AND EXPERIMENTAL IMMUNOLOGY. 2002;130(2):263-270
Response of in vivo protein synthesis in T lymphocytes and leucocytes to an endotoxin challenge in healthy volunteers
Januszkiewicz A; Loré K; Essén P; Andersson B; McNurlan MA; Garlick PJ; Ringdén O; Andersson J; Wernerman J
Article: BLOOD. 2002;100(6):1977-1983
Ursodeoxycholic acid for the prevention of hepatic complications in allogeneic stem cell transplantation
Ruutu T; Eriksson B; Remes K; Juvonen E; Volin L; Remberger M; Parkkali T; Hägglund H; Ringdén O
Article: STEM CELLS AND DEVELOPMENT. 2002;11(4):669-674
Cytolytic T cell reactivity to Epstein-Barr virus is lost during in vitro T cell expansion
Carlens S; Liu D; Ringdén O; Aschan J; Christensson B; Levitsky V; Dilber MS
Article: AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY. 2002;187(2):475-482
Prenatal T-cell reconstitution after in utero transplantation with fetal liver cells in a patient with X-linked severe combined immunodeficiency
Westgren M; Ringdén O; Bartmann P; Bui TH; Lindton B; Mattsson J; Uzunel M; Zetterquist H; Hansmann M
Article: BLOOD. 2002;100(2):406-414
Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse
Lee SJ; Klein JP; Barrett AJ; Ringden O; Antin JH; Cahn JY; Carabasi MH; Gale RP; Giralt S; Hale GA; Ilhan O; McCarthy PL; Socie G; Verdonck LF; Weisdorf DJ; Horowitz MM
Article: TRANSPLANT INFECTIOUS DISEASE. 2002;4(2):75-79
CMV retinitis after allogeneic bone marrow transplantation: a report of five cases.
Larsson K; Lönnqvist B; Ringdén O; Hedquist B; Ljungman P
Article: CLINICAL AND EXPERIMENTAL IMMUNOLOGY. 2002;119(1):240-249
Long-term persistence of oligoclonal serum IgM repertoires in patients treated with allogeneic bone marrow transplantation (BMT)
Björk IN; Brissac C; Remberger M; Mattsson J; Klaesson S; Ringdén O; Stewart J; Lundkvist I
Article: TRANSPLANTATION. 2002;73(6):930-936
Clinical tolerance after allogeneic hematopoietic stem cell transplantation -: A study of influencing factors
Hentschke P; Remberger M; Mattsson J; Barkholt L; Aschan J; Ljungman P; Ringdén O
Article: BONE MARROW TRANSPLANTATION. 2002;29(5):391-397
Association between pretransplant Thymoglobulin and reduced non-relapse mortality rate after marrow transplantation from unrelated donors
Remberger M; Storer B; Ringdén O; Anasetti C
Article: BLOOD. 2002;99(5):1572-1577
Effect of tolerance to noninherited maternal antigens on the occurrence of graft-versus-host disease after bone marrow transplantation from a parent or an HLA-haploidentical sibling
van Rood JJ; Loberiza FR; Zhang MJ; Oudshoorn M; Claas F; Cairo MS; Champlin RE; Gale RP; Ringdén O; Hows JM; Horowitz MH
Article: FETAL DIAGNOSIS AND THERAPY. 2002;17(2):104-109
In vitro studies of haematopoietic colony-forming capacity of human fetal liver cells at exposure to cytotoxic and immunomodulatory drugs
Lindton B; Markling L; Ringdén O; Westgren M
Article: TRANSPLANTATION AND CELLULAR THERAPY. 2002;8(12):674-682
Risk factors for moderate-to-severe chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation
Remberger M; Kumlien G; Aschan J; Barkholt L; Hentschke P; Ljungman P; Mattsson J; Svennilson J; Ringdén O
Article: SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES. 2002;34(5):347-350
Leukocyte depleted, unscreened blood products give a low risk for CMV infection and disease in CMV seronegative allogeneic stem cell transplant recipients with seronegative stem cell donors
Ljungman P; Larsson K; Kumlien G; Aschan J; Barkholt L; Gustaffson-Jernberg Å; Lewensohn-Fuchs I; Ringdén O
Article: CLINICAL AND EXPERIMENTAL IMMUNOLOGY. 2001;123(1):162-169
Poor immune reconstitution after four or five major HLA antigens mismatched T cell-depleted allogeneic and autologous stem cell transplantation
Mattsson J; Uzunel M; Remberger M; Tammik L; Omazic B; Levitsky V; Zou JZ; Hentschke P; Ringdén O
Article: BLOOD. 2001;98(13):3569-3574
Busulfan plus cyclophosphamide compared with total-body irradiation plus cyclophosphamide before marrow transplantation for myeloid leukemia:: long-term follow-up of 4 randomized studies
Socié G; Clift RA; Blaise D; Devergie A; Ringden O; Martin PJ; Remberger M; Deeg HJ; Ruutu T; Michallet M; Sullivan KM; Chevret S
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2001;115(4):935-944
Mixed chimaerism is common at the time of acute graft-versus-host disease and disease response in patients receiving non-myeloablative conditioning and allogeneic stem cell transplantation
Mattsson J; Uzunel M; Brune M; Hentschke P; Barkholt L; Stierner U; Aschan J; Ringdén O
Article: BONE MARROW TRANSPLANTATION. 2001;28(12):1161-1166
A graft-versus-colonic cancer effect of allogeneic stem cell transplantation
Zetterquist H; Hentschke P; Thörne A; Wernerson A; Mattsson J; Uzunel M; Martola J; Albiin N; Aschan J; Papadogiannakis N; Ringdén O
Article: LEUKEMIA. 2001;15(12):1976-1985
Leukemia lineage-specific chimerism analysis is a sensitive predictor of relapse in patients with acute myeloid leukemia and myelodysplastic syndrome after allogeneic stem cell transplantation
Mattsson J; Uzunel M; Tammik L; Aschan J; Ringdén O
Article: LAKARTIDNINGEN. 2001;98(45):4991-4995
[Stem cell transplantation in metastasized renal cancer].
Ringdén O; Brune M
Article: METABOLISM-CLINICAL AND EXPERIMENTAL. 2001;50(11):1308-1314
A combined stress hormone infusion decreases in vivo protein synthesis in human T lymphocytes in healthy volunteers
Januszkiewicz A; Essén P; McNurlan MA; Ringdén O; Garlick PJ; Wernerman J
Article: BONE MARROW TRANSPLANTATION. 2001;28(7):657-664
Population pharmacokinetic analysis resulting in a tool for dose individualization of busulphan in bone marrow transplantation recipients
Sandström M; Karlsson MO; Ljungman P; Hassan Z; Jonsson EN; Nilsson C; Ringden O; Öberg G; Bekassy A; Hassan M
Article: BLOOD. 2001;98(6):1982-1984
The significance of graft-versus-host disease and pretransplantation minimal residual disease status to outcome after allogeneic stem cell transplantation in patients with acute lymphoblastic leukemia
Uzunel M; Mattsson J; Jaksch M; Remberger M; Ringdén O
Article: BLOOD. 2001;98(6):1739-1745
No difference in graft-versus-host disease, relapse, and survival comparing peripheral stem cells to bone marrow using unrelated donors
Remberger M; Ringdén O; Blau IW; Ottinger H; Kremens B; Kiehl MG; Aschan J; Beelen DW; Basara N; Kumlien G; Fauser AA; Runde V
Article: PEDIATRIC TRANSPLANTATION. 2001;5(4):285-292
Polyclonal anti-T-cell globulin as part of the preparative regimen for pediatric allogeneic stem-cell transplantation
Remberger M; Mattsson J; Ringdén O
Article: JOURNAL OF CLINICAL ONCOLOGY. 2001;19(14):3406-3414
No disadvantage in outcome of using matched unrelated donors as compared with matched sibling donors for bone marrow transplantation in children with acute lymphoblastic leukemia in second remission
Saarinen-Pihkala UM; Gustafsson G; Ringdén O; Heilmann C; Glomstein A; Lönnerholm G; Abrahamsson J; Bekassy AN; Schroeder H; Mellander L
Article: CLINICAL NUTRITION. 2001;20(2):181-182
Determination of in vivo protein synthesis in human T lymphocytes
Januszkiewicz A; Essén P; McNurlan MA; Ringdén O; Garlick PJ; Wernerman J
Article: BLOOD. 2001;97(6):1598-1603
Impact of donor type on outcome of bone marrow transplantation for Wiskott-Aldrich syndrome:: collaborative study of the International Bone Marrow Transplant registry and the National Marrow Donor Program
Filipovich AH; Stone JV; Tomany SC; Ireland M; Kollman C; Pelz CJ; Casper JT; Cowan MJ; Edwards JR; Fasth A; Gale RP; Junker A; Kamani NR; Loechelt BJ; Pietryga DW; Ringdén O; Vowels M; Hegland J; Williams AV; Klein JP; Sobocinski KA; Rowlings PA; Horowitz MM
Article: BONE MARROW TRANSPLANTATION. 2001;27(5):479-485
Pharmacokinetics of liposomal busulphan in man
Hassan Z; Ljungman P; Ringdén O; Winiarski J; Nilsson C; Aschan J; Whitley HR; Hassan M
Article: TRANSPLANTATION. 2001;71(3):433-439
T cell mixed chimerism is significantly correlated to a decreased risk of acute graft-versus-host disease after allogeneic stem cell transplantation
Mattsson J; Uzunel M; Remberger M; Ringdén O
Article: CLINICAL MICROBIOLOGY AND INFECTION. 2001;7:68-79
Liposomal amphotericin B (AmBisome) for fungal infections in immunocompromised adults and children
Tollemar J; Klingspor L; Ringdén O
Article: TRANSPLANTATION AND CELLULAR THERAPY. 2001;7(1):31-38
The role of disease stage in the response to donor lymphocyte infusions as treatment for leukemic relapse
Carlens S; Remberger M; Aschan J; Ringdén O
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 2001;66(1):50-56
An ethnic role for chronic, but not acute, graft-versus-host disease after HLA-identical sibling stem cell transplantation
Remberger M; Aschan J; Lönnqvist B; Carlens S; Gustafsson B; Hentschke P; Klaesson S; Mattsson J; Ljungman P; Ringdén O
Article: FETAL DIAGNOSIS AND THERAPY. 2001;16(1):26-31
Recombinant parvovirus B19 empty capsids inhibit fetal hematopoietic colony formation in vitro
Lindton B; Tolfvenstam T; Norbeck O; Markling L; Ringdén O; Westgren M; Broliden K
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2000;111(3):774-781
High levels of human herpesvirus 6 DNA in peripheral blood leucocytes are correlated to platelet engraftment and disease in allogeneic stem cell transplant patients
Ljungman P; Wang FZ; Clark DA; Emery VC; Remberger M; Ringdén O; Linde A
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2000;111(4):1130-1137
Is there a graft-versus-leukaemia effect in the absence of graft-versus-host disease in patients undergoing bone marrow transplantation for acute leukaemia?
Ringdén O; Labopin M; Gorin NC; Schmitz N; Schaefer UW; Prentice HG; Bergmann L; Jouet JP; Mandelli F; Blaise D; Fouillard L; Frassoni F
Article: BONE MARROW TRANSPLANTATION. 2000;26(10):1057-1060
Is it safe to treat allogeneic stem cell transplant recipients at home during the pancytopenic phase? -: A pilot trial
Svahn BM; Bjurman B; Myrbäck KE; Aschan J; Ringdén O
Article: JOURNAL OF NEUROIMMUNOLOGY. 2000;111(1-2):210-214
MHC antigen expression in human first trimester spinal cord with implications for clinical transplantation procedures
Åkesson E; Markling L; Kjældgaard A; Falci S; Ringdén O
Article: BONE MARROW TRANSPLANTATION. 2000;26(7):775-779
Scintigraphic study of the major salivary glands in pediatric bone marrow transplant recipients
Bågesund M; Richter S; Ågren B; Ringdén O; Dahllöf G
Article: THERAPEUTIC DRUG MONITORING. 2000;22(4):383-385
Ketobemidone may alter busulfan pharmacokinetics during high-dose therapy
Hassan M; Svensson JO; Nilsson C; Hentschke P; AL-Shurbaji A; Aschan J; Ljungman P; Ringdén O
Article: BLOOD. 2000;95(12):3996-4003
T-cell depletion of bone marrow transplants for leukemia from donors other than HLA-identical siblings:: advantage of T-cell antibodies with narrow specificities
Champlin RE; Passweg JR; Zhang MJ; Rowlings PA; Pelz CJ; Atkinson KA; Barrett AJ; Cahn JY; Drobyski WR; Gale RP; Goldman JM; Gratwohl A; Gordon-Smith EC; Henslee-Downey PJ; Herzig RH; Klein JP; Marmont AM; O'Reilly RJ; Ringdén O; Slavin S; Sobocinski KA; Speck B; Weiner RS; Horowitz MM
Article: BLOOD. 2000;95(12):3702-3709
Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation
Champlin RE; Schmitz N; Horowitz MM; Chapuis B; Chopra R; Cornelissen JJ; Gale RP; Goldman JM; Loberiza FR; Hertenstein B; Klein JP; Montserrat E; Zhang MJ; Ringdén O; Tomany SC; Rowlings PA; Van Hoef MEHM; Gratwohl A
Article: BLOOD. 2000;95(11):3323-3327
Effect of nucleated marrow cell dose on relapse and survival in identical twin bone marrow transplants for leukemia
Barrett AJ; Ringdén O; Zhang MJ; Bashey A; Cahn JY; Cairo MS; Gale RP; Gratwohl A; Locatelli F; Martino R; Schultz KR; Tiberghien P
Article: TRANSPLANTATION. 2000;69(10):2043-2048
Transplantation of autologous and allogeneic bone marrow with liver from a cadaveric donor for primary liver cancer
Ringdén O; Söderdahl G; Mattsson J; Uzunel M; Remberger M; Hentschke P; Hägglund H; Sparrelid E; Elmhorn-Rosenborg A; Duraj F; Zetterquist H; Ericzon BG
Article: BONE MARROW TRANSPLANTATION. 2000;25(10):1059-1065
Unrelated bone marrow transplantation in children:: outcome and a comparison with sibling donor grafting
Gustafsson Å; Remberger M; Winiarski J; Ringdén O
Article: BONE MARROW TRANSPLANTATION. 2000;25(10):1053-1058
The dismal outcome in patients with acute leukaemia who relapse after an autograft is improved if a second autograft or a matched allograft is performed
Ringdén O; Labopin M; Gorin NC; Meloni G; Blaise D; Reiffers J; Carlson K; Fouillard L; Frassoni F
Article: BONE MARROW TRANSPLANTATION. 2000;25(9):993-996
N-acetylcysteine for hepatic veno-occlusive disease after allogeneic stem cell transplantation
Ringdén O; Remberger M; Lehmann S; Hentschke P; Mattsson J; Klaesson S; Aschan J
Article: BONE MARROW TRANSPLANTATION. 2000;25(9):915-924
The effect of busulphan on the pharmacokinetics of cyclophosphamide and its 4-hydroxy metabolite:: time interval influence on therapeutic efficacy and therapy-related toxicity
Hassan M; Ljungman P; Ringdén O; Hassan Z; Öberg G; Nilsson C; Békassy A; Bielenstein M; Abdel-Rehim M; Georén S; Astner L
Article: TRANSPLANTATION. 2000;69(8):1582-1586
Serum immunoglobulin levels in relation to levels of specific antibodies in allogeneic and autologous bone marrow transplant recipients
Hammarström V; Pauksen K; Svensson H; Lönnqvist B; Simonsson B; Ringdén O; Ljungman P
Article: BONE MARROW TRANSPLANTATION. 2000;25(8):843-851
Mixed chimerism in the B cell lineage is a rapid and sensitive indicator of minimal residual disease in bone marrow transplant recipients with pre-B cell acute lymphoblastic leukemia
Zetterquist H; Mattsson J; Uzunel M; Näsman-Björk I; Svenberg P; Tammik L; Bayat G; Winiarski J; Ringdén O
Article: FETAL DIAGNOSIS AND THERAPY. 2000;15(2):71-78
Mixed lymphocyte culture of human fetal liver cells
Lindton B; Markling L; Ringdén O; Kjaeldgaard A; Gustafson O; Westgren M
Article: ACTA ANAESTHESIOLOGICA SCANDINAVICA. 2000;44(2):202-209
In vivo protein synthesis of circulating human T lymphocytes does not respond to a cortisol challenge within 24 h
Januszkiewicz A; Essén P; McNurlan MA; Ringdén O; Wernerman J; Garlick PJ
Article: LEUKEMIA. 2000;14(2):247-254
Minimal residual disease is common after allogeneic stem cell transplantation in patients with B cell chronic lymphocytic leukemia and may be controlled by graft-versus-host disease
Mattsson J; Uzunel M; Remberger M; Ljungman P; Kimby E; Ringdén O; Zetterquist H
Article: BLOOD. 2000;95(3):807-814
Epstein-Barr virus (EBV) load in bone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease:: prophylactic infusion of EBV-specific cytotoxic T cells
Gustafsson Å; Levitsky V; Zou JZ; Frisan T; Dalianis T; Ljungman P; Ringden O; Winiarski J; Ernberg I; Masucci MG
Article: BONE MARROW TRANSPLANTATION. 1999;24(9):1033-1035
Bilateral subdural haematomas following lumbar puncture in three haematopoietic stem cell transplant recipients
Hentschke P; Hägglund H; Mattsson J; Carlens S; Lönnqvist B; Ljungman P; Aschan J; Fredrikson S; Ringdén O
Article: BONE MARROW TRANSPLANTATION. 1999;24(8):831-836
A prospective randomized trial of Filgrastim (r-metHuG-CSF) given at different times after unrelated bone marrow transplantation
Hägglund H; Ringdén O; Öman S; Remberger M; Carlens S; Mattsson J
Article: BONE MARROW TRANSPLANTATION. 1999;24(8):823-830
Effect on cytokine release and graft-versus-host disease of different anti-T cell antibodies during conditioning for unrelated haematopoietic stem cell transplantation
Remberger M; Svahn BM; Hentschke P; Löfgren C; Ringdén O
Article: BONE MARROW TRANSPLANTATION. 1999;24(6):629-635
Low-dose cyclosporine of short duration increases the risk of mild and moderate GVHD and reduces the risk of relapse in HLA-identical sibling marrow transplant recipients with leukaemia
Carlens S; Aschan J; Remberger M; Dilber MS; Ringdén O
Article: BONE MARROW TRANSPLANTATION. 1999;24(4):389-396
Allogeneic bone marrow transplant or second autograft in patients with acute leukemia who relapse after an autograft
Ringdén O; Labopin M; Frassoni F; Sanz GF; Demeocq F; Prentice HG; Cahn JY; Barbui T; Meloni G; Schaefer UW; Reiffers J; Gorin NC
Article: BLOOD. 1999;94(2):455-464
Peripheral blood stem cell transplantation from unrelated donors:: A comparison with marrow transplantation
Ringdén O; Remberger M; Runde V; Bornhäuser M; Blau IW; Basara N; Hölig K; Beelen DW; Hägglund H; Basu O; Ehninger G; Fauser AA
Article: BLOOD. 1999;93(7):2196-2201
Increased risk of chronic graft-versus-host disease, obstructive bronchiolitis, and alopecia with busulfan versus total body irradiation:: Long-term results of a randomized trial in allogeneic marrow recipients with leukemia
Ringdén O; Remberger M; Ruutu T; Nikoskelainen J; Volin L; Vindelov L; Parkkali T; Lenhoff S; Sallerfors B; Mellander L; Ljungman P; Jacobsen N
Article: BONE MARROW TRANSPLANTATION. 1999;23(6):555-560
Allogeneic bone marrow transplantation in second remission of childhood acute lymphoblastic leukemia:: a population-based case control study from the Nordic countries
Schroeder H; Gustafsson G; Saarinen-Pihkala UM; Glomstein A; Jonmundsson G; Nysom K; Ringdén O; Mellander L
Article: BONE MARROW TRANSPLANTATION. 1999;23(3):283-290
Fungal prophylaxis by reduction of fungal colonization by oral administration of bovine anti-Candida antibodies in bone marrow transplant recipients
Tollemar J; Gross N; Dolgiras N; Jarstrand C; Ringdén O; Hammarström L
Article: MYCOSES. 1999;42(4):239-247
PCR and other non-culture methods for diagnosis of invasive Candida infections in allogeneic bone marrow and solid organ transplant recipients
Chryssanthou E; Klingspor L; Tollemar J; Petrini B; Larsson L; Christensson B; Ringdén O
Article: BLOOD. 1998;92(12):4568-4572
Norethisterone treatment, a major risk-factor for veno-occlusive disease in the liver after allogeneic bone marrow transplantation
Hägglund H; Remberger M; Klaesson S; Lönnqvist B; Ljungman P; Ringdén O
Article: BONE MARROW TRANSPLANTATION. 1998;22(11):1119-1122
Improved peripheral nerve conduction, EEG and verbal IQ after bone marrow transplantation for adult metachromatic leukodystrophy
Solders G; Celsing G; Hagenfeldt L; Ljungman P; Isberg B; Ringdén O
Article: TRANSPLANTATION. 1998;66(10):1330-1334
Results of different strategies for reducing:: Cytomegalovirus-associated mortality in allogeneic stem cell transplant recipients
Ljungman P; Aschan J; Lewensohn-Fuchs I; Carlens S; Larsson K; Lönnqvist B; Mattsson J; Sparrelid E; Winiarski J; Ringdén O
Article: BONE MARROW TRANSPLANTATION. 1998;22(8):795-800
Bacteraemia during the aplastic phase after allogeneic bone marrow transplantation is associated with early death from invasive fungal infection
Sparrelid E; Hägglund H; Remberger M; Ringdén O; Lönnqvist B; Ljungman P; Andersson J
Article: BONE MARROW TRANSPLANTATION. 1998;22(8):755-761
Risk factors for chronic graft-versus-host disease after bone marrow transplantation:: a retrospective single centre analysis
Carlens S; Ringdén O; Remberger M; Lönnqvist B; Hägglund H; Klaesson S; Mattsson J; Svahn BM; Winiarski J; Ljungman P; Aschan J
Article: TRANSPLANTATION. 1998;66(5):620-625
Low incidence of acute graft-versus-host disease, using unrelated HLA-A-, HLA-B-, and HLA-DR-compatible donors and conditioning, including, anti-T-cell antibodies
Ringdén O; Remberger M; Carlens S; Hagglund H; Mattsson J; Aschan J; Lönnqvist B; Klaesson S; Winiarski J; Dalianis T; Olerup O; Sparrelid E; Elmhorn-Rosenborg A; Svahn BM; Ljungman P
Article: BONE MARROW TRANSPLANTATION. 1998;22(5):499-501
Detection of hepatitis G virus GB virus C after allogeneic bone marrow transplantation
Ljungman P; Halasz R; Hägglund H; Sönnerborg A; Ringdén O
Article: BONE MARROW TRANSPLANTATION. 1998;22(2):131-136
Faster neutrophil and platelet engraftment, but no differences in acute GVHD or survival, using peripheral blood stem cells from related and unrelated donors, compared to bone marrow
Hägglund H; Ringdén O; Remberger M; Lönnqvist B; Sparrelid E; Tammik L; Kumlien G
Article: ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA. 1998;77(6):591-593
Increased serum concentrations of interleukin-2 receptor in the first trimester in women who later developed severe preeclampsia
Eneroth E; Remberger M; Vahlne A; Ringden O
Article: BONE MARROW TRANSPLANTATION. 1998;22(1):73-78
Booster marrow or blood cells for graft failure after allogeneic bone marrow transplantation
Remberger M; Ringdén O; Ljungman P; Hägglund H; Winiarski J; Lönnqvist B; Aschan J
Article: PEDIATRIC TRANSPLANTATION. 1998;2(2):150-156
Engraftment and chimerism, particularly of T- and B-cells, in children undergoing allogeneic bone marrow transplantation.
Winiarski J; Mattsson J; Gustafsson A; Wester D; Borgström B; Ringdén O; Ljungman P; Dalianis T
Article: BONE MARROW TRANSPLANTATION. 1998;21(10):995-1003
Allogeneic bone marrow transplantation vs filgrastim-mobilised peripheral blood progenitor cell transplantation in patients with early leukaemia:: first results of a randomised multicentre trial of the European Group for Blood and Marrow Transplantation
Schmitz N; Bacigalupo A; Hasenclever D; Nagler A; Gluckman E; Clark P; Bourquelot P; Greinix H; Frickhofen N; Ringdén O; Zander A; Apperley JF; Gorin C; Borkett K; Schwab G; Goebel M; Russell NH; Gratwohl A
Article: CLINICAL TRANSPLANTATION. 1998;12(2):84-92
Risk factors in bone marrow transplant recipients with leukaemia. Increased relapse risk in patients treated with ciprofloxacin for gut decontamination
Carlens S; Ringden O; Aschan J; Hagglund H; Ljungman P; Mattsson J; Remberger M
Article: BONE MARROW TRANSPLANTATION. 1998;21(4):331-335
Intraosseous compared to intravenous infusion of allogeneic bone marrow
Hägglund H; Ringdén O; Ågren B; Wennberg L; Remberger M; Rundquist L; Svahn BM; Aspelin P
Article: BONE MARROW TRANSPLANTATION. 1998;21(1):79-84
Cadaveric bone marrow and spleen cells for transplantation
Söderdahl G; Tammik C; Remberger M; Ringdén O
Article: BONE MARROW TRANSPLANTATION. 1998;21(1):43-49
Transplantation with unrelated bone marrow in leukaemic patients above 40 years of age
Ringdén O; Remberger M; Mattsson J; Aschan J; Carlens S; Hägglund H; Lönnqvist B; Sparrelid E; Ljungman P
Article: BONE MARROW TRANSPLANTATION. 1997;20(11):909-913
High busulfan concentrations are associated with increased transplant-related mortality in allogeneic bone marrow transplant patients
Ljungman P; Hassan M; Bekassy AN; Ringden O; Oberg G
Article: PEDIATRIC TRANSPLANTATION. 1997;1(2):124-129
Prophylaxis and therapy using liposomal amphotericin B (AmBisome) for invasive fungal infections in children undergoing organ or allogeneic bone-marrow transplantation.
Ringdén O; Andström EE; Remberger M; Dahllöf G; Svahn BM; Tollemar J
Article: JOURNAL OF NEUROTRAUMA. 1997;14(11):875-884
Obliteration of a posttraumatic spinal cord cyst with solid human embryonic spinal cord grafts: First clinical attempt
Falci S; Holtz A; Akesson E; Azizi M; Ertzgaard P; Hultling C; Kjaeldgaard A; Levi R; Ringden O; Westgren M; Lammertse D; Seiger A
Article: SUPPORTIVE CARE IN CANCER. 1997;5(6):485-488
Peroperative teicoplanin for prevention of gram-positive infections in neutropenic patients with indwelling central venous catheters: a randomized, controlled study
Ljungman P; Hagglund H; Bjorkstrand B; Lonnqvist B; Ringden O
Article: TRANSPLANTATION. 1997;64(8):1207-1208
Successful allogeneic bone marrow transplantation in a 2.5-year-old boy with ongoing cytomegalovirus viremia and severe aplastic anemia after orthotopic liver transplantation on for non-A, non-B, non-C hepatitis
Hagglund H; Winiarski J; Ringden O; Sparrelid E; Ericzon BG
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 1997;59(4):254-262
Serum levels of cytokines after bone marrow transplantation: increased IL-8 levels during severe veno-occlusive disease of the liver
Remberger M; Ringden O
Article: ORAL ONCOLOGY. 1997;33(5):327-331
Risk factors for salivary dysfunction in children 1 year after bone marrow transplantation
Dahllof G; Bagesund M; Remberger M; Ringden O
Article: BONE MARROW TRANSPLANTATION. 1997;20(6):479-483
Impact of conditioning regimens on salivary function, caries-associated microorganisms and dental caries in children after bone marrow transplantation. A 4-year longitudinal study
Dahllof G; Bagesund M; Ringden O
Article: TRANSFUSION. 1997;37(7):678-684
Generation of cytokines in red cell concentrates during storage is prevented by prestorage white cell reduction
Shanwell A; Kristiansson M; Remberger M; Ringden O
Article: ACTA PAEDIATRICA. 1997;86(5):484-492
Treatment of adrenoleukodystrophy with bone marrow transplantation
Malm G; Ringden O; Anvret M; vonDobeln U; Hagenfeldt L; Isberg B; Knuutila S; Nennesmo I; Winiarski J; Marcus C
Article: BONE MARROW TRANSPLANTATION. 1997;19(10):963-968
Donor search or autografting in patients with acute leukaemia who lack an HLA-identical sibling? A matched-pair analysis
Ringden O; Labopin M; Gluckman E; Hows JM; Bradley BA; Kolb HJ; Fouillard L; Jacobsen N; Vernant JP; Witz F; Harousseau JL; Gorin NC
Article: BONE MARROW TRANSPLANTATION. 1997;19(9):905-908
Ribavirin therapy in bone marrow transplant recipients with viral respiratory tract infections
Sparrelid E; Ljungman P; EkelofAndstrom E; Aschan J; Ringden O; Winiarski J; Wahlin B; Andersson J
Article: LANCET. 1997;349(9050):476
12-year follow-up of allogeneic bone-marrow transplant for Langerhans' cell histiocytosis
Ringden O; Lonnqvist B; Holst M
Article: BONE MARROW TRANSPLANTATION. 1997;19(3):233-236
No prevention of cytomegalovirus infection by anti-cytomegalovirus hyperimmune globulin in seronegative bone marrow transplant recipients
Ruutu T; Ljungman P; Brinch L; Lenhoff S; Lonnqvist B; Ringden O; Ruutu P; Volin L; Albrechtsen D; Sallerfors B; Ebeling F; Myllyla G
Article: AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY. 1997;176(1):49-53
Tissue distribution of transplanted fetal liver cells in the human fetal recipient
Westgren M; Ek S; Bui TH; Jansson B; Kjaeldgaard A; Markling L; Nennesmo I; Seiger A; Sarby B; Thornstrom S; Ringden O
Article: LEUKEMIA & LYMPHOMA. 1996;24(1-2):71-79
The highest leukaemia-free survival after allogeneic bone marrow transplantation is seen in patients with grade I acute graft-versus-host disease
Ringden O; Hermans J; Labopin M; Apperley J; Gorin NC; Gratwohl A
Article: BONE MARROW TRANSPLANTATION. 1996;18(6):1179-1181
Rejection of the second allogeneic graft in a patient with severe aplastic anemia reversed by antilymphocyte globulin and donor lymphocyte infusions
Ljungman P; Lawler M; Lonnqvist B; Ringden O; Shanwell A
Article: BONE MARROW TRANSPLANTATION. 1996;18(5):921-929
Graft-versus-leukemia effect in allogeneic marrow transplant recipients with acute leukemia is maintained using cyclosporin A combined with methotrexate as prophylaxis
Ringden O; Labopin M; Gluckman E; Reiffers J; Vernant JP; Jouet JP; Harrousseau JL; Fiere D; Bacigalupo A; Frassoni F; Gorin NC
Article: TRANSPLANTATION. 1996;62(8):1076-1080
Treatment of hepatic venoocclusive disease with recombinant human tissue plasminogen activator or orthotopic liver transplantation after allogeneic bone marrow transplantation
Hagglund H; Ringden O; Ericzon BG; Duraj F; Ljungman P; Lonnqvist B; Winiarski J; Tyden G
Article: FETAL DIAGNOSIS AND THERAPY. 1996;11(5):326-334
Colony formation of human fetal CD34+ hematopoietic cells
Ek S; Markling L; Ringden O; Kjeldgaard A; Westgren M
Article: FETAL DIAGNOSIS AND THERAPY. 1996;11(5):318-325
Cytokine stimulation of human fetal hematopoietic cells
Ek S; Westgren M; Markling L; Kjeldgaard A; Ringden O
Article: BONE MARROW TRANSPLANTATION. 1996;18(3):637-639
Evidence of induced non-tolerance in HLA-identical twins with hemoglobinopathy after in utero fetal transplantation
Orlandi F; Giambona A; Messana F; Marino M; Abate I; Calzolari R; Damiani F; Jakil C; Renda M; Dieli F; Buscemi F; Westgren M; Ringden O; Maggio A
Article: BONE MARROW TRANSPLANTATION. 1996;18(2):333-337
Loss of seroreactivity against human papillomavirus (HPV) in bone marrow transplant recipients
LewensohnFuchs I; Ljungman P; Kjerrstrom A; Ringden O; Dalianis T
Article: CLINICAL INFECTIOUS DISEASES. 1996;23(1):167-169
Oral ribavirin for prevention of severe liver disease caused by hepatitis C virus during allogeneic bone marrow transplantation
Ljungman P; Andersson J; Aschan J; Bjorkstrand B; Hagglund H; Lonnqvist B; Ringden O; Winiarski J
Article: BONE MARROW TRANSPLANTATION. 1996;17(6):1003-1008
Clinical outcome in four children with metachromatic leukodystrophy treated by bone marrow-transplantation
Malm G; Ringden O; Winiarski J; Grondahl E; Uvebrant P; Eriksson U; Hakansson H; Skjeldal O; Mansson JE
Article: BRITISH JOURNAL OF HAEMATOLOGY. 1996;93(3):637-645
A comparison of busulphan versus total body irradiation combined with cyclophosphamide as conditioning for autograft or allograft bone marrow transplantation in patients with acute leukaemia
Ringden O; Labopin M; Tura S; Arcese W; Iriondo A; Zittoun R; Sierra J; Gorin NC
Article: MYCOSES. 1996;39(5-6):185-193
Safety and efficacy of liposomal amphotericin B in allogeneic bone marrow transplant recipients
Andstrom EE; Ringden O; Remberger M; Svahn BM; Tollemar J
Article: SCANDINAVIAN JOURNAL OF IMMUNOLOGY. 1996;43(5):574-582
Inhibition of immunoglobulin production in vitro by IgG and F(ab')(2) fragments, but not by the Fc portion
Klaesson S; Tammik L; Markling L; Lundkvist I; Ringden O
Article: TRANSPLANTATION. 1996;61(8):1176-1179
Lack of evidence of permanent engraftment after in utero fetal stem cell transplantation in congenital hemoglobinopathies
Westgren M; Ringden O; EikNes S; Ek S; Anvret M; Brubakk AM; Bui TH; Giambona A; Kiserud T; Kjaeldgaard A; Maggio A; Markling L; Seiger A; Orlandi F
Article: BONE MARROW TRANSPLANTATION. 1996;17(4):583-587
Use of a semi-quantitative PCR for cytomegalovirus DNA as a basis for pre-emptive antiviral therapy in allogeneic bone marrow transplant patients
Ljungman P; Lore K; Aschan J; Klaesson S; LewensohnFuchs I; Lonnqvist B; Ringden O; Winiarski J; Ehrnst A
Article: BONE MARROW TRANSPLANTATION. 1996;17(3):357-363
Allogeneic bone marrow transplantation in first remission for children with very high-risk acute lymphoblastic leukemia: A retrospective case-control study in the Nordic countries
Saarinen UM; Mellander L; Nysom K; Ringden O; Schroeder H; Glomstein A; Gustafsson G
Article: ACTA PAEDIATRICA. 1996;85(3):327-335
Bone marrow transplantation in children using unrelated donors at Huddinge Hospital
Winiarski J; Ringden O; Remberger M; Dalianis T; Ljungman P; Borgstrom B
Article: ACTA PAEDIATRICA. 1996;85(2):168-172
Fungal pneumonia: The predominant lung infection causing death in children undergoing bone marrow transplantation
Heurlin N; Bergstrom SE; Winiarski J; Ringden O; Ljungman P; Lonnqvist B; Andersson J
Article: TRANSPLANTATION. 1995;60(11):1293-1299
Increased levels of soluble interleukin-2 receptor in veno-occlusive disease of the liver after allogenic bone marrow transplantation
Remberger M; Ringden O
Article: TRANSPLANTATION. 1995;60(11):1225-1230
Does high-dose intravenous immune globulin treatment after bone marrow transplantation increase mortality in veno-occlusive disease of the liver?
Klaesson S; Ringden O; Ljungman P; Aschan J; Hagglund H; Winiarski J
Article: BONE MARROW TRANSPLANTATION. 1995;16(6):747-753
Risk factors for acute graft-versus-host disease in 291 consecutive HLA-identical bone marrow transplant recipients
Hagglund H; Bostrom L; Remberger M; Ljungman P; Nilsson B; Ringden O
Article: TRANSPLANTATION. 1995;60(9):961-965
CYTOMEGALOVIRUS DNA IN PERIPHERAL-BLOOD LEUKOCYTES AND PLASMA FROM BONE-MARROW TRANSPLANT RECIPIENTS
BRYTTING M; MOUSAVIJAZI M; BOSTROM L; LARSSON M; LUNDEBERG J; LJUNGMAN P; RINGDEN O; SUNDQVIST VA
Article: DRUG SAFETY. 1995;13(4):207-218
LIPID FORMULATIONS OF AMPHOTERICIN-B - LESS TOXICITY BUT AT WHAT ECONOMIC COST
TOLLEMAR J; RINGDEN O
Article: BLOOD. 1995;86(4):1614-1618
LONG-TERM EFFECTS OF HEPATITIS-C VIRUS-INFECTION IN ALLOGENEIC BONE-MARROW TRANSPLANT RECIPIENTS
LJUNGMAN P; JOHANSSON N; ASCHAN J; GLAUMANN H; LONNQVIST B; RINGDEN O; SPARRELID E; SONNERBORG A; WINIARSKI J; GAHRTON G
Article: OBSTETRICS AND GYNECOLOGY. 1995;86(2):209-213
CYTOKINES IN FETAL BLOOD AND AMNIOTIC-FLUID IN RH-IMMUNIZED PREGNANCIES
WESTGREN M; EK S; REMBERGER M; RINGDEN O; STANGENBERG M
Article: LANCET. 1995;345(8962):1398-1402
ALLOGENEIC BONE-MARROW TRANSPLANTATION FOR LYSOSOMAL STORAGE DISEASES
HOOGERBRUGGE PM; BROUWER OF; BORDIGONI P; RINGDEN O; KAPAUN P; ORTEGA JJ; OMEARA A; CORNU G; SOUILLET G; FRAPPAZ D; BLANCHE S; FISCHER A
Article: BONE MARROW TRANSPLANTATION. 1995;15(6):869-871
BUSULFAN CONCENTRATION IN RELATION TO PERMANENT ALOPECIA IN RECIPIENTS OF BONE-MARROW TRANSPLANTS
LJUNGMAN P; HASSAN M; BEKASSY AN; RINGDEN O; OBERG G
Article: BONE MARROW TRANSPLANTATION. 1995;15(4):619-625
SIMILAR INCIDENCE OF GRAFT-VERSUS-HOST DISEASE USING HLA-A, HLA-B AND HLA-DR IDENTICAL UNRELATED BONE-MARROW DONORS AS WITH HLA-IDENTICAL SIBLINGS
RINGDEN O; REMBERGER M; PERSSON U; LJUNGMAN P; ALDENER A; ANDSTROM E; ASCHAN J; BOLME P; DAHLLOF G; DALIANIS T; GAHRTON G; HAGGLUND H; LONNQVIST B; OLERUP O; SHANWELL A; SPARRELID E; WINIARSKI J; MOLLER E; OBERG M
Article: TRANSPLANTATION. 1995;59(6):864-870
10 YEARS EXPERIENCE OF BONE-MARROW TRANSPLANTATION FOR GAUCHER DISEASE
RINGDEN O; GROTH CG; ERIKSON A; GRANQVIST S; MANSSON JE; SPARRELID E
Article: BONE MARROW TRANSPLANTATION. 1995;15(3):331-335
ALLOGENEIC BONE-MARROW TRANSPLANTATION FOR HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS IN SWEDEN
BOLME P; HENTER JI; WINIARSKI J; ELINDER G; LJUNGMAN P; LONNERHOLM G; RINGDEN O
Article: CLINICAL AND DIAGNOSTIC VIROLOGY. 1995;3(2):139-153
CMV PCR MONITORING IN LEUKOCYTES OF TRANSPLANT PATIENTS
EHRNST A; BARKHOLT L; LEWENSOHNFUCHS I; LJUNGMAN P; TEODOSIU O; STALAND A; RINGDEN O; TYDEN G; JOHANSSON B
Article: TRANSPLANTATION. 1995;59(1):45-50
LIPOSOMAL AMPHOTERICIN-B PREVENTS INVASIVE FUNGAL, INFECTIONS IN LIVER-TRANSPLANT RECIPIENTS - A RANDOMIZED, PLACEBO-CONTROLLED STUDY
TOLLEMAR J; HOCKERSTEDT K; ERICZON BG; JALANKO H; RINGDEN O
Article: NORDISK MEDICIN. 1995;110(12):302-304
[Theme: bone marrow transplantation. Introduction and future outlook].
Ringdén O
Article: BONE MARROW TRANSPLANTATION. 1995;15(1):99-104
TNF-ALPHA LEVELS ARE INCREASED DURING BONE-MARROW TRANSPLANTATION CONDITIONING IN PATIENTS WHO DEVELOP ACUTE GVHD
REMBERGER M; RINGDEN O; MARKLING L
Show more

All other publications

Review: FRONTIERS IN IMMUNOLOGY. 2022;13:839844
Mesenchymal Stromal Cells for Enhancing Hematopoietic Engraftment and Treatment of Graft-Versus-Host Disease, Hemorrhages and Acute Respiratory Distress Syndrome
Ringden O; Moll G; Gustafsson B; Sadeghi B
Corrigendum: BONE MARROW TRANSPLANTATION. 2021;56(9):2319
Impact of depth of clinical response on outcomes of acute myeloid leukemia patients in first complete remission who undergo allogeneic hematopoietic cell transplantation (Apr, 10.1038/s41409-021-01261-6, 2021)
Percival M-E; Wang H-L; Zhang M-J; Saber W; de Lima M; Litzow M; Kebriaei P; Abdel-Azim H; Adekola K; Aljurf M; Bacher U; Badawy SM; Beitinjaneh A; Bejanyan N; Bhatt V; Byrne M; Cahn J-Y; Castillo P; Chao N; Chhabra S; Copelan E; Cutler C; DeFilipp Z; Dias A; Diaz MA; Estey E; Farhadfar N; Frangoul HA; Freytes CO; Gale RP; Ganguly S; Gowda L; Grunwald M; Hossain N; Kamble RT; Kanakry CG; Kansagra A; Kharfan-Dabaja MA; Krem M; Lazarus HM; Lee JW; Liesveld JL; Lin R; Liu H; McGuirk J; Munker R; Murthy HS; Nathan S; Nishihori T; Olsson RF; Palmisiano N; Passweg JR; Prestidge T; Ringden O; Rizzieri DA; Rybka WB; Savoie ML; Schultz KR; Seo S; Sharma A; Solh M; Strair R; van der Poel M; Verdonck LF; Yared JA; Weisdorf D; Sandmaier BM
Corrigendum: HAEMATOLOGICA. 2021;106(8):2295-2296
Impact of cytogenetic abnormalities on outcomes of adult Philadelphia-negative acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation: a study by the Acute Leukemia Working Committee of the Center for International Blood and Marrow Transplant Research.
Lazaryan A; Dolan M; Zhang M-J; Wang H-L; Kharfan-Dabaja MA; Marks DI; Bejanyan N; Copelan E; Majhail NS; Waller EK; Chao N; Prestidge T; Nishihori T; Kebriaei P; Inamoto Y; Hamilton B; Hashmi SK; Kamble RT; Bacher U; Hildebrandt GC; Stiff PJ; McGuirk J; Aldoss I; Beitinjaneh AM; Muffly L; Vij R; Olsson RF; Byrne M; Schultz KR; Aljurf M; Seftel M; Savoie ML; Savani BN; Verdonck LF; Cairo MS; Hossain N; Bhatt VR; Frangoul HA; Abdel-Azim H; Al Malki M; Munker R; Rizzieri D; Khera N; Nakamura R; Ringdén O; Van der Poel M; Murthy HS; Liu H; Mori S; De Oliveira S; Bolaños-Meade J; Elsawy M; Barba P; Nathan S; George B; Pawarode A; Grunwald M; Agrawal V; Wang Y; Assal A; Caro PC; Kuwatsuka Y; Seo S; Ustun C; Politikos I; Lazarus HM; Saber W; Sandmaier BM; De Lima M; Litzow M; Bachanova V; Weisdorf D
Review: BLOOD REVIEWS. 2020;43:100669
Can we prevent or treat graft-versus-host disease with cellular-therapy?
Zahid MF; Lazarus HM; Ringden O; Barrett JA; Gale RP; Hashmi SK
Editorial comment: CLINICAL PHARMACOLOGY & THERAPEUTICS. 2020;107(2):308
Protocol Changes Lead to Lowering of SOS Rates
Review: TRENDS IN MOLECULAR MEDICINE. 2019;25(2):149-163
Intravascular Mesenchymal Stromal/Stem Cell Therapy Product Diversification: Time for New Clinical Guidelines
Moll G; Ankrum JA; Kamhieh-Milz J; Bieback K; Ringden O; Volk H-D; Geissler S; Reinke P
Letter: LAKARTIDNINGEN. 2016;113:DUYW
[Important that Sweden allows new treatments on vital indication].
Ringdén O
Review: LANCET HAEMATOLOGY. 2016;3(1):e45-e52
Survival after mesenchymal stromal cell therapy in steroid-refractory acute graft-versus-host disease: systematic review and meta-analysis
Hashmi S; Ahmed M; Murad MH; Litzow MR; Adams RH; Ball LM; Prasad VK; Kebriaei P; Ringden O
Letter: BONE MARROW TRANSPLANTATION. 2015;50(7):1007-1009
Bone marrow aspiration technique has deteriorated in recent years
Remberger M; Ringden O; Mattsson J
Letter: LANCET RESPIRATORY MEDICINE. 2015;3(4):e12
Untitled Reply
Ringden O
Letter: TRANSPLANTATION. 2014;98(12):e95-e96
Allogeneic Hematopoietic Cell Transplantation for GATA2 Deficiency in a Patient With Disseminated Human Papillomavirus Disease
Maeurer M; Magalhaes I; Andersson J; Ljungman P; Sandholm E; Uhlin M; Mattsson J; Ringden O
Editorial comment: BLOOD. 2014;124(25):3672-3673
GVHD prophylaxis made safe, easy, and inexpensive
Ringden O
Letter: BONE MARROW TRANSPLANTATION. 2014;49(12):1541-1542
Twenty-year follow-up of a randomized trial comparing intraosseous and i.v. BM transplantation
Hagglund H; Remberger M; Ringden O
Other: TRANSPLANTATION. 2014;98(2):122-123
In Memoriam-Carl-Gustav Groth 1933-2014
Ericzon B-G; Lundgren G; Tibell A; Tyden G; Ringden O
Review: BONE MARROW TRANSPLANTATION. 2014;49(6):737-743
Stromal cells-are they really useful for GVHD?
Kaipe H; Erkers T; Sadeghi B; Ringden O
Letter: INTERNATIONAL JOURNAL OF HEMATOLOGY. 2012;96(6):822-824
Treatment of severe acute graft-versus-host disease with mesenchymal stromal cells: a comparison with non-MSC treated patients
Remberger M; Ringden O
Editorial comment: TRANSPLANTATION AND CELLULAR THERAPY. 2012;18(11):1615-1617
Is Graft-versus-Leukemia More Effective Using Reduced-Intensity Conditioning Compared with Myeloablative Conditioning?
Ringden O; Sadeghi B
Letter: BONE MARROW TRANSPLANTATION. 2011;46(8):1158-1160
Pooled MSCs for treatment of severe hemorrhage
Ringden O; LeBlanc K
Meeting abstract: TRANSPLANTATION AND CELLULAR THERAPY. 2011;17(2):S287
BONE MARROW OR PERIPHERAL BLOOD STEM CELL TRANSPLANTATION FROM UNRELATED DONORS IN ADULT PATIENTS WITH ACUTE MYELOID LEUKEMIA
Ringden O; Labopin M; Beelen DW; Volin L; Ehninger G; Finke J; Greinix HT; Kyrcz-Krzemien S; Bunjes D; Brinch L; Niederwieser D; Arnold R; Mohty M; Rocha V
Editorial comment: BONE MARROW TRANSPLANTATION. 2011;46(2):163-164
Mesenchymal stromal cells as treatment for chronic GVHD
Ringden O; Keating A
Review: BRITISH JOURNAL OF HAEMATOLOGY. 2009;147(5):614-633
The allogeneic graft-versus-cancer effect
Ringden O; Karlsson H; Olsson R; Omazic B; Uhlin M
Meeting abstract: BLOOD. 2009;114(22):1306
Comparison of Busulfan and Cyclophosphamide (Bu-Cy)-Based Standard Myeloablative Conditioning (MAC) Vs. Fludarabine and Busulfan (Flu-Bu)-Based Reduced-Intensity Conditioning (RIC) Prior to Allogeneic Stem Cell Transplantation (allo-SCT) From An HLA Identical Sibling Donor for Acute Myeloid Leukemia (AML) Patients in First Complete Remission (CR1) Aged >40 Years: a Retrospective Analysis From the Acute Leukemia Working Party of EBMT
Mohty M; Labopin M; Socie G; Milpied N-J; Attal M; Blaise D; Ringden O; Brown P; Lorentz B; Brune ML; Hamladji R-M; Duarte RF; Nagler A; Rocha V
Editorial comment: STEM CELLS AND DEVELOPMENT. 2009;18(9):1243-1246
Mesenchymal Stromal Cells as First-Line Treatment of Graft Failure After Hematopoietic Stem Cell Transplantation
Ringden O
Meeting abstract: HUMAN IMMUNOLOGY. 2009;70:S100
MAINTAINED TOLERANCE OF NK CELLS EXPRESSING INHIBITORY KIR FOR NON-SELF LIGANDS IN HLA-MATCHED SIBLING STEM CELL TRANSPLANTATION
Schaffer M; Bjorklund A; Fauriat C; Ringden O; Remberger M; Ljungman P; Ljunggren H-G; Malmberg K-J
Editorial comment: PEDIATRIC TRANSPLANTATION. 2009;13(3):272-277
Pediatric Transplantation: Ten years on
Benden C; Dipchand AI; Danziger-Isakov LA; Esquivel CO; Ringden O; Wray J; Marks SD
Editorial comment: LANCET ONCOLOGY. 2009;10(5):440-442
Immune reconstitution after HLA mismatched haemopoietic stem-cell transplantation
Ringden O; Karlsson H; Omazic B
Meeting abstract: TRANSPLANTATION AND CELLULAR THERAPY. 2009;15(2):85
INCREASED FREQUENCY AND RESPONSIVENESS OF PSA-SPECIFIC T CELLS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION FOR PROSTATE CANCER
Mattsson J; Okas M; Ringden O; Uhlin M
Meeting abstract: TRANSPLANTATION AND CELLULAR THERAPY. 2009;15(2):21-22
RISKS AND BENEFITS OF UNRELATED DONOR PERIPHERAL BLOOD PROGENITOR CELL S (PBSC) IN CHILDREN AND ADOLESCENTS WITH ACUTE LEUKEMIA
Ringden O; Eapen M; Locatelli F; Champlin RE; Frangoul HA; Remberger M; Gee AP; Laughlin MJ; Rocha V
Meeting abstract: TRANSPLANTATION AND CELLULAR THERAPY. 2009;15(2):114
STABLE MIXED DONOR-DONOR CHIMERISM AFTER DOUBLE CORD BLOOD TRANSPLANTATION
Gertow J; Berglund S; Okas M; Ringden O; Ublin M; Mattsson J
Meeting abstract: TRANSPLANTATION AND CELLULAR THERAPY. 2009;15(2):59
GVHD PROPHYLAXIS USING LOW-DOSE CYCLOSPORINE IS SAFE AND REDUCES THE RISK OF RELAPSE AND DEATH IN LEUKEMIC RECIPIENTS OF HLA-IDENTICAL SIBLING TRANSPLANTS
Olsson R; Remberger M; Mattsson J; Hassan Z; Ringden O
Meeting abstract: TRANSPLANTATION AND CELLULAR THERAPY. 2009;15(2):130-131
CLINICAL EXPANSION OF CORD BLOOD DERIVED T CELLS FOR USE AS DONOR LYMPHOCYTE INFUSION AFTER CORD BLOOD TRANSPLANTATION
Okas M; Gertow J; Uzunel M; Karlsson H; Uzunel M; Ringden O; Mattsson J; Ublin M
Meeting abstract: TRANSPLANTATION AND CELLULAR THERAPY. 2009;15(2):127
N-ACETYL-L-CYSTEINE PROMOTES T CELL MEDIATED IMMUNITY IN ALLOGENEIC SETTINGS IN VIVO AND IN VITRO
Karlsson H; Nava S; Remberger M; Hassan Z; Hassan M; Ringden O
Meeting abstract: TRANSPLANTATION AND CELLULAR THERAPY. 2009;15(2):47
HLA MISMATCHED MSC SUPPRESS T LYMPHOCYTE ALLORESPONSES IN VITRO AND DO NOT INDUCE IMMUNOLOGICAL MEMORY IN RECIPIENTS OF MSC INFUSION
Sundin M; Barrett J; Ringden O; Uzunel M; Lonnies H; Dackland A-L; Christensson B; Le Blanc K
Meeting abstract: TRANSPLANTATION AND CELLULAR THERAPY. 2009;15(2):47
THE IMPORTANCE OF GRAFT CELL COMPOSITION TO OUTCOME AFTER ALLOGENEIC STEM CELL TRANSPLANTATION
Svenberg P; Ringden O; Uzunel M
Meeting abstract: TRANSPLANTATION AND CELLULAR THERAPY. 2009;15(2):46
TREATMENT OF THREATENING REJECTION AFTER UMBILICAL CORD BLOOD TRANSPLANTATION WITH EX VIVO EXPANDED CB DERIVED T CELLS
Uhlin M; Okas M; Gertow J; Ringden O; Mattsson J
Review: LAKARTIDNINGEN. 2008;105(51-52):3731-3735
[Progress on lysosomal diseases yields hope for cure and improvement].
Malm G; von Döbeln U; Naess K; Ringdén O
Letter: BONE MARROW TRANSPLANTATION. 2008;42(11):769-771
Using reduced intensity conditioning and HLA-identical sibling donors, antithymocyte globulin increases the risk of relapse, which can be overcome by a high stem cell dose
Remberger M; Mattsson J; Svahn B-M; Ringden O
Letter: LANCET. 2008;372(9640):716
Mesenchymal stem cells for acute graft-versus-host disease -: Reply
Le Blanc K; Fibbe W; Frassoni F; Locatelli F; Ringden O
Meeting abstract: TRANSPLANTATION AND CELLULAR THERAPY. 2008;14(2):144
MINIMAL RESIDUAL DISEASE AND CHIMERISM IN CML PATIENTS RECEIVING ALLOGENEIC TRANSPLANTS AFTER MYELOABLATIVE OR REDUCED CONDITIONING
Uzunel M; Mattsson J; Hauzenberger D; Ringden O
Meeting abstract: TRANSPLANTATION AND CELLULAR THERAPY. 2008;14(2):48-49
MESENCHYMAL STEM CELLS EXERT DIFFERENTIAL EFFECTS ON ALLO-ANTIGEN- AND VIRUS-SPECIFIC T CELLS
Karlsson H; Samarasinghe S; Ball L; Sundberg B; Lankester AC; Dazzi F; Rao K; Veys P; Le Blanc K; Ringden O; Amrolia PJ
Meeting abstract: TRANSPLANTATION AND CELLULAR THERAPY. 2008;14(2):46
CLINICAL ISOLATION AND EX VIVO CULTURING OF CORD BLOOD-DERIVED T CELLS FOR DONOR LYMPHOCYTE INFUSION
Uhlin M; Ringden O; Mattson J
Meeting abstract: BLOOD. 2007;110(11):327A-328A
Recent decrease in acute GVHD and increased relapse in children with leukemia receiving unrelated donor bone marrow transplants
Davies SM; Wang D; Wang T; Arora A; Ringden O; Anasetti C; Pavletic S; Casper J; MacMillan ML; Sanders J; Wall D; Kernan NA
Meeting abstract: BLOOD. 2007;110(11):2969-872A
Prospecitve quantitative PCR monitoring of allogeneic stem cell transplant (SCT) patients at high risk for EBV associated PTLD
Omar H; Hagglund H; Gustafsson-Jernberg A; Le Blanc K; Mattson J; Remberger M; Ringden O; Sparrelid E; Sundin M; Winiarski JH; Yun Z; Ljungman PT
Review: JOURNAL OF INTERNAL MEDICINE. 2007;262(5):509-525
Immunomodulation by mesenchymal stem cells and clinical experience
Le Blanc K; Ringden O
Editorial comment: MEDICAL ONCOLOGY. 2007;24(3):354-356
Relapse of preB-ALL after rituximab treatment for chronic graft versus host disease.: Implications for its use?
Deneberg S; Lerner R; Ljungman P; Ringden O; Hagglund H
Meeting abstract: TRANSPLANTATION AND CELLULAR THERAPY. 2007;13(2):47
Tissue repair using allogeneic mesenchymal stem cells for hemorrhagic cystitis, pneumomediastinum and perforated colon
Ringden O; Uzunel M; Sundberg B; Lonnies L; Nava S; Gotherstrom C; Gustafsson J; Henningsohn L; Le Blanc K
Meeting abstract: TRANSPLANTATION AND CELLULAR THERAPY. 2007;13(2):97
Major ABO blood group mismatch increases the risk for graft failure after unrelated donor hematopoietic stem cell transplantation
Remberger M; Watz E; Ringden O; Mattsson J; Shanwell A; Wikman A
Meeting abstract: TRANSPLANTATION AND CELLULAR THERAPY. 2007;13(2):46
Co-transplantation of mesenchymal stem cells and hematopoietic stem cells
Le Blanc K; Sundberg B; Lonnies H; Aschan J; Barkbolt L; Gustafsson B; Ringden O
Review: MECHANISMS AND THERAPY OF LIVER CANCER. 2007;97:25-60
Immunotherapy by allogeneic stem cell transplantation
Ringden O
Meeting abstract: BLOOD. 2006;108(11):97A
Effect of busulphan dose adjustment on regimen-related toxicity.
Hassan Z; Remberger M; Ringden O; Oberg G; Bekassy AN; Hassan M
Review: CURRENT OPINION IN IMMUNOLOGY. 2006;18(5):586-591
Mesenchymal stem cells:: properties and role in clinical bone marrow transplantation
Le Blanc K; Ringden O
Meeting abstract: HUMAN IMMUNOLOGY. 2006;67(10):S129
KIR-HLA mismatch in T-cell replete HLA-identical sibling hematopoietic stem cell transplantation for acute myelogenous leukemia
Schaffer M; Remberger M; Ringden O; Ljunggren H-G; Malmberg K-J
Letter: BONE MARROW TRANSPLANTATION. 2006;38(4):321-322
Myeloablative conditioning for hematopoietic stem cell transplantation in patients with non-malignant diseases
Ringden O; Svenberg P; Le Blanc K; Mattsson J; Remberger M
Letter: TRANSPLANTATION AND CELLULAR THERAPY. 2006;12(6):693-694
Mesenchymal stem cells combined with cyclosporine inhibits cytotoxic T cells
Ringdén O; Le Blanc K
Meeting abstract: TRANSPLANTATION AND CELLULAR THERAPY. 2006;12(2):126
Allogeneic hematopoietic stem cell transplantation for inherited disorders: Experience in a single-center
Mattson J; Remberger M; Svahn BM; Svenberg P; Winiarski J; Ringden O
Meeting abstract: TRANSPLANTATION AND CELLULAR THERAPY. 2006;12(2):40
Sensitive and quantitative chimerism analysis in AML patients with real-time PCR
Svenberg P; Uzunel M; Ringdén O
Meeting abstract: TRANSPLANTATION AND CELLULAR THERAPY. 2006;12(2):21
European experience of allogeneic hematopoietic stem cell transplantation for metastatic renal carcinoma: On behalf of the French ITAC group and the EBMT solid tumour working party
Barkholt L; Bregni M; Remberger M; Blaise D; Peccatori J; Massenkeil G; Pedrazzoli P; Zambelli A; Bay JO; Francois S; Martino R; Bengala C; Brune M; Lenhoff S; Porcellini A; Falda M; Siena S; Demirer T; Niederwieser D; Ringden O
Meeting abstract: TRANSPLANTATION AND CELLULAR THERAPY. 2006;12(2):2
Mesenchymal stem cells for treatment of severe acute graft-versus-host disease
Ringden O; Uzunel M; Rasmusson I; Remberger ME; Sundberg B; Lonnies H; Marschall HU; Dlugosz A; Szakos A; Hassan Z; Omazic B; Aschan J; Barkholt L; Le Blanc K
Meeting abstract: BLOOD. 2005;106(11):575A
A phase 3, randomized, placebo-controlled trial of Filgrastim in patients (Pts) with hematologic malignancies (HM) treated with a myeloablative conditioning regimen and allogenic bone marrow transplantation (allo BMT)
Ernst P; Bacigalupo A; Ringdén O; Ruutu T; Zander A; Kolb H; Siegert W; Strijckmans P; Zwaan F; Skacel T
Meeting abstract: BLOOD. 2005;106(11):540A
Effects of photopheresis on mononuclear cells from healthy individuals.
Kumlien G; Remberger M; Ringdén O
Review: APMIS. 2005;113(11-12):813-830
Allogeneic hematopoietic stem cell transplantation:: state of the art and new perspectives
Ringdén O; Le Blanc K
Published conference paper: JOURNAL OF CLINICAL ONCOLOGY. 2005;23(24):5788-5794
Unrelated donor marrow transplantation for B-Cell chronic lymphocytic leukemia after using myeloablative conditioning:: Results from the center for international blood and marrow transplant research
Pavletic SZ; Khouri IF; Haagenson M; King RJ; Bierman PJ; Bishop MR; Carston M; Giralt S; Molina A; Copelan EA; Ringdén O; Roy V; Ballen K; Adkins DR; McCarthy P; Weisdorf D; Montserrat E; Anasetti C
Review: TRANSPLANTATION AND CELLULAR THERAPY. 2005;11(5):321-334
Immunobiology of human mesenchymal stem cells and future use in hematopoietic stem cell transplantation
Le Blanc K; Ringdén O
Other: HAEMATOLOGICA. 2005;90(4):438
Use of mesenchymal stem cells for the prevention of immune complications of hematopoietic stem cell transplantation.
Le Blanc K; Ringdén O
Meeting abstract: TRANSPLANTATION AND CELLULAR THERAPY. 2005;11(2):33
Transplantation after reduced intensity conditioning in patients with acute myeloid leukaemia in Sweden
Aschan J; Ringdén O; Wahlin A; Wernstedt P; Brune M
Published conference paper: TRANSPLANTATION AND CELLULAR THERAPY. 2005;11(2):17-20
Introduction to graft-versus-host disease
Ringdén O
Published conference paper: MOLECULAR IMMUNOLOGY. 2005;42(4):531-534
KIR-ligand mismatch in allogeneic hematopoietic stem cell transplantation
Malmberg KJ; Schaffer M; Ringdén O; Remberger M; Ljunggren HG
Meeting abstract: TRANSPLANTATION AND CELLULAR THERAPY. 2005;11(2):69-70
Human mesenchymal stem cells affect IgG production induced by lipopolysaccharide, cytomegalovirus and varicella zoster virus in human spleen
Rasmusson I; Sundberg B; Le Blanc K; Ringden O
Letter: JOURNAL OF CLINICAL ONCOLOGY. 2005;23(3):649-650
Antiapoptotic effect of growth factors in leukemia -: Reply
Ringdén O
Published conference paper: JOURNAL OF CLINICAL ONCOLOGY. 2004;22(24):4872-4880
Higher mortality after allogeneic peripheral-blood transplantation compared with bone marrow in children and adolescents:: The histocompatibility and alternate stem cell source working committee of the International Bone Marrow Transplant Registry
Eapen M; Horowitz MM; Klein JP; Champlin RE; Loberiza FR; Ringdén O; Wagner JE
Letter: JOURNAL OF CLINICAL ONCOLOGY. 2004;22(21):4430-4432
Myeloid growth factors should not be administered routinely after allogeneic hematopoietic stem-cell transplantation -: In reply
Ringdén O
Letter: LEUKEMIA. 2004;18(8):1430-1433
Low-dose ARAC, donor cells, and GM-CSF for treatment of recurrent acute myeloid leukemia after allogeneic stem cell transplantation
Schmid C; Schleuning M; Aschan J; Ringdén O; Hahn J; Holler E; Hegenbart U; Niederwieser D; Dugas M; Ledderose G; Kolb HJ
Meeting abstract: TRANSPLANTATION AND CELLULAR THERAPY. 2004;10(2):80
Indium-III labelled donor lymphocyte infusion via hepatic artery or IV against liver metastases of renal and colon carcinoma after allogeneic haematopoietic stem cell transplantation
Barkholt L; Danielsson R; Calissendorff B; Svensson L; Malihi R; Uzunel M; Remberger M; Ringden O
Meeting abstract: TRANSPLANTATION AND CELLULAR THERAPY. 2004;10(2):17
Treatment with granulocyte colony-stimulating factor after allogeneic bone marrow transplantation for acute leukemia increases the risk of graft-versus-host disease and death
Ringdén O; Labopin M; Gorin NC; Le Blanc K; Rocha V; Gluckman E; Reiffers J; Arcese W; Vossen JM; Jouet JP; Cordonnier C; Frassoni F
Letter: BONE MARROW TRANSPLANTATION. 2004;33(2):257-258
Urgent need for a validated tumor response evaluation system for use in immunotherapy -: Reply
Barkholt L; Hentschke P; Ringdén O
Editorial comment: TRANSPLANTATION AND CELLULAR THERAPY. 2004;10(2)
Abstracts from the 2004 Tandem BMT Meetings -: American Society for Blood and Marrow Transplantation and International Bone Marrow Transplant Registry/Autologous Blood and Marrow Transplant Registry -: Introductory remarks
Ringdén O; Champlin RE; Negrin R
Editorial comment: PEDIATRIC TRANSPLANTATION. 2003;7(6):422-425
Novel treatment for refractory acute myeloid leukemia
Ringdén O
Meeting abstract: AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY. 2003;189(6):S215
Donor chimerism across full allogenic barriers achieved by in utero transplantation of fetal mesenchymal stem cells in a case of osteogenesis imperfecta
Westgren L; Anneren G; Axelsson O; Evald U; Leblanc K; Ringden O
Editorial comment: TRANSPLANTATION. 2003;76(7):1011-1012
Transplantation of embryonic stem cells:: Possibilities and challenges
Ringdén O; Le Blanc K; Hovatta O
Published conference paper: JOURNAL OF CLINICAL ONCOLOGY. 2002;20(21):4324-4330
Relevance of bone marrow cell dose on allogeneic transplantation outcomes for patients with acute myeloid leukemia in first complete remission:: Results of a European survey
Rocha V; Labopin M; Gluckman E; Powles R; Arcese W; Bacigalupo A; Reiffers J; Iriondo A; Ringdén O; Ruutu T; Frassoni F
Letter: LANCET. 2002;359(9309):888
Survival after bone-marrow transplantation
Remberger M; Ringdén O
Published conference paper: JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 2002;49:51-55
Ten years' experience with liposomal amphotericin B in transplant recipients at Huddinge University Hospital
Ringdén O
Review: CLINICAL TRANSPLANTATION. 2001;15(3):147-153
Treatment of severe acute graft-versus-host disease with anti-thymocyte globulin
Remberger M; Aschan J; Barkholt L; Tollemar J; Ringdén O
Published conference paper: TRANSPLANTATION PROCEEDINGS. 2001;33(1-2):1862-1864
An allogeneic anti-cancer effect after hematopoietic stem cell transplantation
Barkholt L; Hentschke P; Zetterquist H; Mattsson J; Uzunel M; Wersäll P; Martola J; Albin N; Aschan J; Wijkström H; Tillegård A; Öman S; Wernerson A; Niederwieser D; Thörne A; Ringdén O
Published conference paper: TRANSPLANTATION PROCEEDINGS. 2001;33(1-2):1769-1770
An ethnic role for chronic, but not acute, graft-versus-host disease after HLA-identical sibling stem cell transplantation
Remberger M; Aschan J; Lönnqvist B; Carlens S; Gustafsson B; Hentschke P; Klaesson S; Mattsson J; Ljungman P; Ringdén O
Published conference paper: BONE MARROW TRANSPLANTATION. 2000;25:S6-S8
Faster engraftment of neutrophils and platelets with peripheral blood stem cells from unrelated donors:: a comparison with marrow transplantation
Ringdén O; Remberger M; Runde V; Bornhäuser M; Blau IW; Basara N; Hölig K; Beelen DW; Hägglund B; Basu O; Ehninger G; Fauser AA
Meeting abstract: GASTROENTEROLOGY. 2000;118(4):A1414
Tumor reduction surgery followed by allogeneic stem cell transplantation. A treatment for disseminated gastrointestinal cancer?
Thorne A; Zetterquist H; Hentchke P; Mattsson J; Uzunel M; Aschan J; Ohman S; Ringden O
Letter: BONE MARROW TRANSPLANTATION. 2000;25(3):342-343
Side-effects of amphotericin B lipid complex (Abelcet) in the Scandinavian population -: Response
Ringdén O; Tollemar J
Meeting abstract: TRANSPLANTATION. 1999;67(7):S144
Fungal prophylaxis by oral administration of bovine anti-Candida antibodies in allogeneic BMT
Tollemar J; Gross N; Torner P; Jarstrand C; Hammarstrom L; Ringdén O
Letter: BONE MARROW TRANSPLANTATION. 1998;22(7):733-734
Severe and common side-effects of amphotericin B lipid complex (Abelcet)
Ringden O; Jonsson V; Hansen M; Tollemar J; Jacobsen N
Letter: TRANSPLANTATION. 1998;66(1):142-143
Transplantation of peripheral blood progenitor cells from unrelated donors
Ringdén O; Runde V; Hägglund H; Basu O; Potter M
Published conference paper: BONE MARROW TRANSPLANTATION. 1998;21:S81-S84
Faster engraftment of peripheral blood progenitor cells compared to bone marrow from unrelated donors
Ringdén O; Hägglund H; Runde V; Basu O; Kroschinsky F; Stockschläder M; Potter MN
Published conference paper: TRANSPLANTATION PROCEEDINGS. 1997;29(7):3147-3149
Factors affecting risk of relapse and leukemia-free survival in HLA-identical sibling marrow transplant recipients with leukemia
Carlens S; Ringden O; Remberger M; Mattsson J; Aschan J; Hagglund H; Ljungman P
Published conference paper: TRANSPLANTATION PROCEEDINGS. 1997;29(7):3145-3146
Transplantation with unrelated bone marrow in leukemic patients above 40 years of age
Ringden O; Remberger M; Mattsson J; Aschan J; Hagglund H; Carlens S; Lonnqvist B; Sparrelid E; Ljungman P
Review: MEDICAL ONCOLOGY. 1997;14(1):11-22
Bone marrow transplantation using unrelated donors for haematological malignancies
Ringden O
Published conference paper: TRANSPLANTATION PROCEEDINGS. 1997;29(1-2):735-736
A low incidence of grade II to IV acute GVHD, but high mortality from, infection using HLA-A, -B, and -DR-identical unrelated donors and immunosuppression with ATG, cyclosporine, and methotrexate
Mattsson J; Ringden O; Aschan J; Barkholt L; Dalianis T; Hagglund H; Ljungman P; Lonnqvist B; Tollemar J; Winiarski J; Remberger M
Published conference paper: TRANSPLANTATION PROCEEDINGS. 1997;29(1-2):733-734
Strong antileukemic effect of chronic graft-versus-host disease in allogeneic marrow transplant recipients having acute leukemia treated with methotrexate and cyclosporine
Ringden O; Labopin M; Gluckman E; Reiffers J; Vernant JP; Jouet JP; Harousseau JL; Fiere D; Bacigalupo A; Frassoni F; Gorin NC
Published conference paper: TRANSPLANTATION PROCEEDINGS. 1997;29(1-2):714-715
Immune markers and hematopoiesis of cadaveric bone marrow for transplantation
Soderdahl G; Tammik C; Remberger M; Sandberg J; Tufveson G; Tollemar J; Ringden O
Review: ACTA ONCOLOGICA. 1997;36(6):549-564
Allogeneic bone marrow transplantation for hematological malignancies - Controversies and recent advances
Ringden O
Review: BONE MARROW TRANSPLANTATION. 1996;18(5):831-837
In utero haematopoietic stem cell transplantation: Current perspectives and future potential
Jones DRE; Bui TH; Anderson EM; Ek S; Liu DTY; Ringden O; Westgren M
Letter: LANCET. 1996;348(9023):346
Graft-versus-myeloma effect
Aschan J; Lonnqvist B; Ringden O; Kumlien G; Gahrton G
Letter: INFECTION. 1996;24(3):269
No increase in cyclosporin neurotoxicity in transplant recipients treated with liposomal amphotericin B
Ringden O; Andstrom EE; Remberger M; Svahn BM; Tollemar J
Published conference paper: BONE MARROW TRANSPLANTATION. 1996;17:S62-S64
Transplantation of peripheral blood progenitor cells from unrelated donors
Ringden O; Potter MN; Oakhill A; Cornish J; Hagglund H; Lonnqvist B; Shanwell A; Winiarski J; Pamphilon DH
Letter: BONE MARROW TRANSPLANTATION. 1995;16(6):856-857
Transplantation with peripheral blood stem cells from unrelated donors without serious graft-versus-host disease
Ringden O; Lonnqvist B; Hagglund H; Ljungman P; Shanwell A; Lawlor E; Schmitz N
Published conference paper: TRANSPLANTATION PROCEEDINGS. 1995;27(6):3536-3537
Intravenous immunoglobulin: Immune modulatory effects in vitro and clinical effects in allogeneic bone marrow transplant recipients
Klaesson S; Ringden O; Markling L; Tammik L
Published conference paper: TRANSPLANTATION PROCEEDINGS. 1995;27(6):3535
No beneficial effects, but severe side effects caused by recombinant human tissue plasminogen activator for treatment of hepatic veno-occlusive disease after allogeneic bone marrow transplantation
Hagglund H; Ringden O; Ljungman P; Winiarski J; Ericzon B; Tyden G
Published conference paper: TRANSPLANTATION PROCEEDINGS. 1995;27(6):3533-3534
Cytokines in veno-occlusive disease of the liver after bone marrow transplantation
Remberger M; Ringden O
Published conference paper: TRANSPLANTATION PROCEEDINGS. 1995;27(6):3531-3532
Bone marrow transplantation for chronic myelogenous leukemia using unrelated donors: The experience at Huddinge Hospital
Aschan J; Ringden O; Ljungman P; Hagglund H; Klaesson S; Dalianis T; Remberger M
Published conference paper: TRANSPLANTATION PROCEEDINGS. 1995;27(6):3530
Risk factors for septicemia during aplastic period after allogeneic bone marrow transplantation
Sparrelid E; Hagglund H; Remberger M; Ljungman P; Malmborg AS; Winiarski J; Andersson J; Ringden O
Published conference paper: TRANSPLANTATION PROCEEDINGS. 1995;27(6):3528-3529
Less acute GVHD in patients receiving totally matched transplants from unrelated donors
Lonnqvist B; Ljungman P; Norrby M; Olerup O; Ringden O; Winiarski J
Other: BONE MARROW TRANSPLANTATION. 1995;15(5):799-801
BONE-MARROW TRANSPLANTATION IN 2 CHILDREN WITH CONGENITAL AMEGAKARYOCYTIC THROMBOCYTOPENIA
HENTER JJ; WINIARSKI J; LJUNGMAN P; RINGDEN O; OST A
Published conference paper: TRANSPLANTATION PROCEEDINGS. 1995;27(1):1195-1198
PROPHYLAXIS WITH LIPOSOMAL AMPHOTERICIN-B (AMBISOME) PREVENTS FUNGAL-INFECTIONS IN LIVER-TRANSPLANT RECIPIENTS - LONG-TERM RESULTS OF A RANDOMIZED, PLACEBO-CONTROLLED TRIAL
TOLLEMAR J; HOCKERSTEDT K; ERICZON BG; JALANKO H; RINGDEN O
Show more

Employments

Affiliated to Research, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, 2022-2025

Degrees and Education

Docent, Karolinska Institutet, 1978

Articles

All other publications

Employments

Degrees and Education

News from KI

Events from KI